Data	O
were	O
available	O
on	O
age	O
at	O
study	O
recruitment	O
,	O
age	O
at	O
cancer	O
diagnosis	O
,	O
age	O
of	O
bilateral	O
prophylactic	O
mastectomy	O
,	O
BRCA12	O
mutation	O
description	O
,	O
and	O
self-reported	O
ethnicity.However	O
,	O
evaluation	O
of	O
stringently	O
predicted	O
RXR	O
binding	O
sites	O
in	O
the	O
AQP5	O
promoter	O
in	O
human	O
and	O
rat	O
shows	O
that	O
the	O
presence	O
of	O
adjacent	O
predicted	O
RAR	O
binding	O
sites	O
is	O
rare	O
or	O
absent	O
,	O
while	O
adjacent	O
predicted	O
VDR	O
sites	O
are	O
more	O
common	O
,	O
and	O
predicted	O
estrogen	O
and	O
glucocorticoid	O
receptor	O
sites	O
also	O
abut	O
RXR	O
binding	O
site	O
56	O
.	O
We	O
postulate	O
that	O
biologic	O
aging	O
in	O
female	O
breast	O
tissue	O
may	O
be	O
accelerated	O
beginning	O
at	O
puberty	O
,	O
and	O
may	O
be	O
linked	O
to	O
stimulation	O
by	O
estrogen	O
,	O
progesterone	O
,	O
and	O
oxytocin	O
,	O
and	O
cell	O
cycling	O
,	O
so	O
that	O
by	O
early	O
adulthood	O
the	O
DNAm	O
age	O
in	O
female	O
breast	O
is	O
higher	O
than	O
that	O
of	O
other	O
tissues	O
,	O
as	O
we	O
observe.One	O
group	O
was	O
characterized	O
by	O
over-expression	O
of	O
ERBB2	O
,	O
the	O
steroid	O
hormone	O
receptor	O
AR	O
,	O
and	O
genes	O
related	O
to	O
steroid	O
estrogen	O
response	O
such	O
as	O
GATA3	O
,	O
TFF1	O
,	O
and	O
DNALI1	O
.	O
Doxorubicin	O
treatment	O
did	O
not	O
alter	O
the	O
hormone	O
receptor	O
status	O
of	O
ex	O
vivo	O
breast	O
tumors	O
,	O
including	O
estrogen	O
and	O
progesterone	O
receptors	O
Figure	O
S1A	O
and	O
B	O
in	O
Additional	O
file	O
1.For	O
tumor	O
grade	O
,	O
receptor	O
status	O
,	O
and	O
histological	O
type	O
,	O
the	O
only	O
significant	O
difference	O
reported	O
in	O
the	O
randomized	O
trials	O
was	O
that	O
women	O
treated	O
with	O
estrogen	O
alone	O
were	O
more	O
likely	O
to	O
have	O
lobular	O
tumors	O
than	O
ductal	O
tumors	O
.	O
Acting	O
through	O
the	O
progesterone	O
receptor	O
,	O
progesterone	O
is	O
the	O
physiological	O
negative	O
regulator	O
of	O
estrogen	O
activation	O
45.Furthermore	O
,	O
CYP2D6*4	O
,	O
which	O
was	O
included	O
to	O
account	O
for	O
the	O
possible	O
differential	O
effect	O
of	O
variable	O
tamoxifen	O
metabolism	O
on	O
outcome	O
among	O
patients	O
whose	O
tumors	O
were	O
estrogen-receptor	O
positive	O
,	O
was	O
included	O
in	O
all	O
the	O
models	O
tested	O
,	O
and	O
there	O
was	O
no	O
independent	O
effect	O
of	O
this	O
genotype	O
,	O
nor	O
did	O
it	O
appear	O
to	O
confound	O
the	O
main	O
effects	O
.	O
As	O
shown	O
in	O
Figure	O
6	O
,	O
treatment	O
with	O
auranofin	O
andor	O
CSNO	O
decreased	O
the	O
levels	O
of	O
cytosolic	O
ERα	O
,	O
compared	O
with	O
control	O
cells	O
,	O
where	O
the	O
absence	O
of	O
the	O
estrogen	O
signal	O
induced	O
higher	O
levels	O
of	O
stabilized	O
cytosolic	O
ERα	O
protein.Sirt1	O
transcription	O
factor	O
has	O
been	O
shown	O
to	O
regulate	O
Hey2	O
,	O
a	O
downstream	O
effecter	O
of	O
Notch1	O
signaling	O
38	O
,39	O
,	O
one	O
of	O
the	O
more	O
prominent	O
activated	O
pathways	O
in	O
the	O
luminal-restricted	O
mammary	O
progenitor	O
cells	O
40	O
,41	O
.	O
We	O
defined	O
hormone	O
receptor	O
positive	O
patients	O
as	O
estrogen	O
andor	O
progesterone	O
receptor	O
positive	O
HR	O
positive	O
and	O
HR-negative	O
if	O
negative	O
for	O
both.Furthermore	O
,	O
preliminary	O
comparisons	O
of	O
the	O
parenchymal	O
patterns	O
of	O
estrogen-receptor	O
positive	O
ER+	O
and	O
negative	O
ER–	O
cancer	O
cases	O
measured	O
with	O
the	O
same	O
methodology	O
51	O
showed	O
that	O
subtype-specific	O
breast	O
cancer	O
risk	O
assessment	O
based	O
on	O
mammographic	O
textures	O
may	O
also	O
be	O
feasible	O
79	O
.	O
However	O
,	O
the	O
role	O
of	O
ERβ	O
in	O
Hes-6	O
regulation	O
is	O
not	O
known	O
and	O
must	O
be	O
clarified	O
in	O
future	O
studies.Among	O
five	O
previous	O
epidemiological	O
studies	O
that	O
examined	O
the	O
effect	O
of	O
alcohol	O
consumption	O
according	O
to	O
ERPR	O
status	O
among	O
young	O
women	O
19	O
,36	O
or	O
premenopausal	O
women	O
12	O
,22	O
,37	O
,	O
two	O
found	O
a	O
10	O
to	O
38	O
%	O
increase	O
in	O
risk	O
of	O
ER+PR+	O
cancer	O
,	O
which	O
was	O
not	O
statistically	O
significant	O
,	O
for	O
women	O
at	O
the	O
highest	O
category	O
of	O
alcohol	O
consumption	O
versus	O
women	O
who	O
had	O
never	O
drunk	O
alcohol	O
22	O
,37	O
;	O
one	O
found	O
an	O
increase	O
in	O
risk	O
of	O
the	O
ER+PR-	O
subtype	O
36	O
;	O
and	O
another	O
found	O
a	O
non-statistically	O
significant	O
increase	O
in	O
risk	O
of	O
both	O
ER+PR+	O
and	O
ER-	O
PR-	O
receptor	O
subtypes	O
19	O
.	O
Here	O
,	O
we	O
have	O
applied	O
comprehensive	O
sequence-based	O
approaches	O
using	O
exome	O
capture	O
and	O
transcriptome	O
sequencing	O
in	O
a	O
breast	O
cancer	O
cell	O
line	O
,	O
HCC1954	O
,	O
to	O
identify	O
potential	O
cancer-specific	O
and	O
somatically	O
driven	O
LOH	O
and	O
ASE	O
events	O
,	O
and	O
to	O
discern	O
their	O
functional	O
characteristics.To	O
determine	O
whether	O
the	O
absence	O
of	O
nuclear	O
colocalisation	O
between	O
TFF1	O
and	O
GREB1	O
was	O
an	O
exception	O
or	O
a	O
more	O
general	O
feature	O
of	O
estrogen	O
induced	O
transcription	O
,	O
we	O
analysed	O
the	O
positioning	O
of	O
the	O
progesterone	O
receptor	O
PGR	O
and	O
Cathepsin-D	O
CTSD	O
genes	O
,	O
both	O
located	O
on	O
different	O
regions	O
of	O
chromosome	O
11	O
.	O
LIF	O
is	O
known	O
to	O
be	O
estrogen	O
responsive	O
;	O
when	O
examined	O
,	O
we	O
did	O
not	O
find	O
significant	O
changes	O
in	O
LIF	O
by	O
qRT-PCR	O
and	O
by	O
immunocytochemistry	O
in	O
mutants	O
in	O
comparison	O
to	O
the	O
controls.The	O
data	O
monitor	O
3	O
,389	O
genes	O
across	O
30	O
estrogen-receptor-negative	O
and	O
28	O
estrogen-receptor-positive	O
breast	O
cancer	O
samples	O
33	O
,34.However	O
,	O
the	O
underlying	O
molecular	O
mechanisms	O
remain	O
undefined	O
.	O
Furthermore	O
,	O
because	O
both	O
tumorigenic	O
and	O
normal	O
nontumorigenic	O
breast	O
cells	O
respond	O
to	O
the	O
opposing	O
actions	O
of	O
5αP	O
and	O
3αHP	O
,	O
the	O
relative	O
concentrations	O
of	O
the	O
progesterone	O
metabolites	O
in	O
the	O
microenvironment	O
may	O
also	O
play	O
a	O
role	O
in	O
maintaining	O
normalcy	O
of	O
breast	O
tissues	O
in	O
general	O
,	O
regardless	O
of	O
ERPR	O
status.The	O
antiestrogenic	O
activity	O
of	O
tamoxifen	O
,	O
by	O
competing	O
with	O
estrogen	O
for	O
binding	O
to	O
the	O
ER	O
in	O
tumor	O
tissue	O
,	O
is	O
considered	O
to	O
be	O
its	O
core	O
mechanism	O
of	O
action	O
,	O
and	O
adjuvant	O
use	O
of	O
tamoxifen	O
after	O
primary	O
resection	O
of	O
ER-positive	O
breast	O
tumor	O
decreases	O
the	O
risk	O
of	O
recurrence	O
27	O
.	O
DEFS	O
,	O
distant	O
event-free	O
survival	O
;	O
MKS	O
,	O
mitotic	O
kinase	O
score	O
;	O
ERS	O
,	O
estrogen-related	O
score	O
;	O
GGI	O
,	O
genomic	O
grade	O
index	O
;	O
Lum	O
,	O
luminal	O
;	O
ER+HER2-lowP	O
,	O
ER-positivehuman	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
HER2-negative	O
low	O
proliferation	O
;	O
ER+HER2-highP	O
,	O
ER-positiveHER2-negative	O
high	O
proliferation	O
;	O
NA	O
,	O
not	O
applicable.For	O
this	O
purpose	O
the	O
regression	O
model	O
is	O
usually	O
adjusted	O
for	O
age	O
,	O
pT	O
stage	O
,	O
grading	O
,	O
hormone	O
estrogen	O
and	O
progesterone	O
receptor	O
as	O
well	O
as	O
ERBB2	O
status	O
38	O
.	O
However	O
,	O
evaluation	O
of	O
stringently	O
predicted	O
RXR	O
binding	O
sites	O
in	O
the	O
AQP5	O
promoter	O
in	O
human	O
and	O
rat	O
shows	O
that	O
the	O
presence	O
of	O
adjacent	O
predicted	O
RAR	O
binding	O
sites	O
is	O
rare	O
or	O
absent	O
,	O
while	O
adjacent	O
predicted	O
VDR	O
sites	O
are	O
more	O
common	O
,	O
and	O
predicted	O
estrogen	O
and	O
glucocorticoid	O
receptor	O
sites	O
also	O
abut	O
RXR	O
binding	O
site	O
56.In	O
addition	O
,	O
it	O
is	O
possible	O
that	O
repression	O
of	O
Hes-6	O
could	O
be	O
important	O
for	O
the	O
breast	O
cancer-suppressive	O
effects	O
of	O
tamoxifen	O
.	O
,	O
intrathymically	O
;	O
mOVA	O
,	O
membrane-bound	O
ovalbumin	O
;	O
NS	O
,	O
not	O
significant	O
;	O
TCR	O
,	O
T	O
cell	O
receptor	O
;	O
Tg	O
,	O
transgenic	O
;	O
TM	O
,	O
tamoxifen	O
;	O
tTcon	O
,	O
thymic	O
conventional	O
T	O
cell	O
;	O
tTreg	O
,	O
thymic	O
regulatory	O
T	O
cell.It	O
has	O
been	O
hypothesized	O
that	O
an	O
ER-	O
stem	O
cell	O
population	O
gives	O
rise	O
to	O
ER+	O
progenitor	O
cells	O
40	O
,	O
which	O
will	O
proliferate	O
when	O
exposed	O
to	O
estrogen	O
,	O
but	O
can	O
also	O
send	O
paracrine	O
signals	O
that	O
will	O
cause	O
neighboring	O
populations	O
of	O
ER-	O
cells	O
to	O
proliferate	O
.	O
In	O
contrast	O
,	O
it	O
could	O
be	O
hypothesized	O
that	O
hormonal	O
factors	O
should	O
affect	O
receptor-positive	O
and	O
receptor-negative	O
breast	O
cancer	O
similarly.The	O
results	O
in	O
this	O
study	O
are	O
consistent	O
with	O
that	O
in	O
other	O
cohorts	O
of	O
triple-negative	O
breast	O
cancer	O
patients	O
,	O
in	O
whom	O
11	O
%	O
to	O
39	O
%	O
have	O
germline	O
mutations	O
in	O
BRCA1	O
and	O
BRCA2	O
3	O
,6	O
,20-23	O
,	O
and	O
cohorts	O
of	O
estrogen-receptor-negative	O
breast	O
cancer	O
patients	O
,	O
of	O
whom	O
24	O
%	O
to	O
29	O
%	O
have	O
germline	O
mutations	O
in	O
BRCA1	O
and	O
BRCA2	O
4	O
,6	O
,24	O
,25	O
.	O
Ncoa4	O
nuclear	O
receptor	O
co-activator	O
4	O
and	O
FOXA1	O
forkhead-box	O
A1	O
,	O
both	O
have	O
been	O
shown	O
to	O
act	O
as	O
transcriptional	O
activators	O
of	O
estrogen	O
ER-α	O
36	O
,37.Here	O
evidence	O
is	O
presented	O
that	O
the	O
progesterone	O
metabolites	O
,	O
5α-pregnane-3	O
,20-dione	O
5α-dihydroprogesterone	O
;	O
5αP	O
and	O
4-pregnen-3α-ol-20-one	O
3α-dihydroprogesterone	O
;	O
3αHP	O
,	O
can	O
regulate	O
ERPR-negative	O
breast	O
cell	O
tumor	O
formation	O
and	O
growth	O
as	O
well	O
as	O
tumor	O
regression	O
and	O
maintenance	O
of	O
normalcy	O
.	O
Additionally	O
,	O
binding	O
of	O
estrogen	O
to	O
the	O
ER	O
can	O
be	O
modulated	O
by	O
progesterone	O
44.CreERT	O
,	O
ubiquitous	O
promoter-driven	O
Cre-recombinase	O
and	O
estrogen-receptor	O
fusion	O
protein	O
;	O
FC	O
,	O
FoxN1fxfxCreERT	O
;	O
FoxN1	O
,	O
Forkhead	O
box	O
protein	O
N1	O
;	O
FoxN1fxfx	O
,	O
loxp-flanked	O
FoxN1	O
gene	O
;	O
IL-2	O
,	O
interleukin-2	O
;	O
NF-κB	O
,	O
Nuclear	O
Factor	O
kappa	O
Beta	O
;	O
RT	O
,	O
reverse	O
transcribed	O
;	O
PCR	O
,	O
polymerase	O
chain	O
reaction	O
;	O
tTreg	O
,	O
thymic	O
regulatory	O
T	O
cell	O
.	O
As	O
shown	O
in	O
Figure	O
5	O
,	O
treatment	O
of	O
estrogen-deprived	O
MCF-7	O
cells	O
with	O
CSNO	O
or	O
auranofin	O
,	O
added	O
separately	O
or	O
in	O
combination	O
,	O
induced	O
an	O
almost	O
exclusively	O
nuclear	O
localization	O
of	O
ERα	O
,	O
with	O
a	O
clear	O
reduction	O
of	O
the	O
cytoplasmic	O
levels	O
of	O
the	O
receptor.CD	O
,	O
cluster	O
of	O
differentiation	O
;	O
CreERT	O
,	O
ubiquitous	O
promoter-driven	O
Cre-recombinase	O
and	O
estrogen-receptor	O
fusion	O
protein	O
;	O
FC	O
,	O
FoxN1fxfxCreERT	O
;	O
FoxN1	O
,	O
Forkhead	O
box	O
protein	O
N1	O
;	O
FoxN1fxfx	O
or	O
FoxN1-floxed	O
,	O
loxp-flanked	O
FoxN1	O
gene	O
;	O
GFP	O
,	O
green	O
fluorescent	O
protein	O
;	O
Teff	O
,	O
T	O
effector	O
cell	O
;	O
tTreg	O
,	O
thymic	O
regulatory	O
T	O
cell	O
;	O
WT	O
,	O
wild-type	O
.	O
,	O
intrathymically	O
;	O
mOVA	O
,	O
membrane-bound	O
ovalbumin	O
;	O
NS	O
,	O
not	O
significant	O
;	O
TCR	O
,	O
T	O
cell	O
receptor	O
;	O
Tg	O
,	O
transgenic	O
;	O
TM	O
,	O
tamoxifen	O
;	O
tTcon	O
,	O
thymic	O
conventional	O
T	O
cell	O
;	O
tTreg	O
,	O
thymic	O
regulatory	O
T	O
cell	O
.	O
Underlying	O
data	O
used	O
in	O
the	O
generation	O
of	O
this	O
figure	O
can	O
be	O
found	O
in	O
S1	O
Data.Bag-1	O
modulates	O
the	O
function	O
of	O
the	O
ER	O
,	O
and	O
enhances	O
estrogen-dependent	O
transcription	O
46	O
.	O
Using	O
qRT-PCR	O
,	O
we	O
confirmed	O
that	O
PGR	O
and	O
CTSD	O
expression	O
was	O
activated	O
upon	O
addition	O
of	O
E2	O
to	O
MCF-7	O
cells	O
Figure	O
4B	O
with	O
relative	O
mRNA	O
levels	O
increasing	O
3	O
and	O
8	O
fold	O
,	O
respectively	O
,	O
after	O
16	O
h	O
exposure	O
to	O
10	O
nM	O
E2.Not	O
only	O
do	O
these	O
receptor-negative	O
breast	O
cancers	O
fail	O
to	O
benefit	O
from	O
current	O
hormonal	O
therapies	O
,	O
but	O
they	O
also	O
generally	O
exhibit	O
more-aggressive	O
biologic	O
behaviors	O
and	O
poorer	O
prognosis	O
than	O
the	O
receptor-positive	O
ones	O
10-14	O
.	O
For	O
all	O
of	O
these	O
series	O
and	O
for	O
our	O
study	O
,	O
BRCA1	O
mutations	O
are	O
more	O
common	O
than	O
BRCA2	O
mutations.To	O
determine	O
whether	O
the	O
capacity	O
of	O
newly	O
generated	O
tTreg	O
cells	O
is	O
impaired	O
in	O
aged	O
thymus	O
17	O
andor	O
in	O
the	O
TEC	O
defect-induced	O
atrophied	O
thymus	O
,	O
we	O
utilized	O
our	O
previously	O
generated	O
mouse	O
model	O
with	O
accelerated	O
thymic	O
atrophy	O
due	O
to	O
postnatal	O
TEC	O
homeostatic	O
defect	O
12	O
,	O
in	O
which	O
the	O
loxp-flanked	O
FoxN1	O
gene	O
FoxN1fxfx	O
18	O
can	O
be	O
deleted	O
by	O
ubiquitous	O
promoter-driven	O
Cre-recombinase	O
and	O
estrogen-receptor	O
fusion	O
protein	O
CreERT	O
mediation	O
through	O
either	O
a	O
tamoxifen	O
TM	O
induction	O
or	O
a	O
CreERT	O
autoleakage	O
with	O
age	O
.	O
The	O
Croce	O
group	O
has	O
shown	O
that	O
miRNAs	O
are	O
aberrantly	O
expressed	O
in	O
human	O
breast	O
cancers	O
and	O
that	O
this	O
expression	O
correlated	O
to	O
multiple	O
features	O
of	O
cancer	O
,	O
including	O
estrogen	O
and	O
progesterone	O
receptor	O
status	O
,	O
stage	O
,	O
and	O
indices	O
of	O
proliferation	O
and	O
invasion	O
7.In	O
this	O
scenario	O
,	O
it	O
has	O
been	O
recently	O
demonstrated	O
that	O
GPER	O
acts	O
as	O
an	O
additional	O
receptor	O
mediating	O
the	O
effects	O
of	O
estrogens	O
in	O
a	O
wide	O
number	O
of	O
cell	O
types	O
,	O
such	O
as	O
breast	O
,	O
endometrial	O
and	O
ovarian	O
cancer	O
cells	O
7	O
.	O
Together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
severity	O
of	O
thymic	O
atrophy	O
positively	O
influences	O
new	O
tTreg	O
cell	O
generation	O
and	O
negatively	O
affects	O
pTreg	O
cells	O
reentering	O
the	O
thymus.N	O
,	O
number	O
of	O
patients	O
;	O
MKS	O
,	O
mitotic	O
kinase	O
score	O
;	O
ERS	O
,	O
estrogen-related	O
score	O
;	O
HER2	O
:	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
.	O
Our	O
findings	O
using	O
immortalized	O
mammary	O
fibroblasts	O
and	O
specific	O
breast	O
cancer	O
cell	O
lines	O
lay	O
the	O
foundation	O
for	O
studying	O
these	O
questions	O
in	O
broader	O
contexts.The	O
data	O
in	O
Additional	O
data	O
file	O
4	O
monitor	O
3	O
,389	O
genes	O
across	O
30	O
estrogen-receptor-negative	O
and	O
28	O
estrogen-receptor-positive	O
breast	O
cancer	O
samples	O
.	O
The	O
index	O
thus	O
designed	O
was	O
applied	O
to	O
a	O
breast	O
cancer	O
dataset	O
that	O
included	O
both	O
DNA	O
copy	O
number	O
and	O
mRNA	O
expression	O
data	O
,	O
showing	O
that	O
inferred	O
JARID1b	O
activity	O
was	O
prognostic	O
for	O
estrogen-receptor-positive	O
disease.In	O
recent	O
years	O
,	O
the	O
genome-wide	O
search	O
for	O
markers	O
predicting	O
prognosis	O
in	O
breast	O
cancer	O
has	O
led	O
to	O
a	O
global	O
picture	O
in	O
which	O
three	O
coordinates	O
representing	O
important	O
biological	O
processes	O
have	O
outstanding	O
prognostic	O
consequences	O
31	O
,35	O
,36	O
:	O
the	O
proliferation	O
metagene	O
,	O
consisting	O
of	O
a	O
group	O
of	O
genes	O
indicating	O
transition	O
from	O
slow	O
to	O
fast	O
proliferation	O
;	O
the	O
B-cell	O
and	O
T-cell	O
metagenes	O
as	O
markers	O
for	O
immune	O
cell	O
infiltration	O
;	O
and	O
estrogen-receptor-dependent	O
genes	O
.	O
TXNIP	O
showed	O
also	O
a	O
weakly	O
positive	O
correlation	O
with	O
the	O
B-cell	O
metagene	O
R	O
=	O
0.278	O
;	O
P	O
<	O
0.001.HRs	O
of	O
death	O
calculated	O
from	O
a	O
multivariate	O
Cox	O
proportional	O
hazards	O
model	O
for	O
patients	O
diagnosed	O
with	O
estrogen-positive	O
tumors	O
who	O
underwent	O
breast-conserving	O
surgery	O
.	O
Risk	O
assessment	O
is	O
of	O
utmost	O
importance	O
because	O
of	O
the	O
well-known	O
side	O
effects	O
of	O
adjuvant	O
treatment	O
and	O
is	O
being	O
conducted	O
by	O
means	O
of	O
TNM	O
classification	O
and	O
differentiation	O
grade	O
complemented	O
by	O
estrogen	O
and	O
progesterone	O
receptor	O
status	O
,	O
Her2neu	O
expression	O
and	O
peritumoral	O
vascular	O
invasion	O
2-6.As	O
shown	O
in	O
Figure	O
5	O
,	O
treatment	O
of	O
estrogen-deprived	O
MCF-7	O
cells	O
with	O
CSNO	O
or	O
auranofin	O
,	O
added	O
separately	O
or	O
in	O
combination	O
,	O
induced	O
an	O
almost	O
exclusively	O
nuclear	O
localization	O
of	O
ERα	O
,	O
with	O
a	O
clear	O
reduction	O
of	O
the	O
cytoplasmic	O
levels	O
of	O
the	O
receptor	O
.	O
Limited	O
to	O
the	O
early	O
stage	O
,	O
7	O
patients	O
19.4	O
%	O
were	O
diagnosed	O
as	O
non-cancer.However	O
,	O
the	O
latter	O
gene	O
also	O
highlights	O
the	O
general	O
difficulty	O
of	O
such	O
analysis	O
.	O
Using	O
hierarchical	O
clustering	O
with	O
Pearson	O
correlation	O
metric	O
and	O
complete	O
linkage	O
,	O
we	O
found	O
that	O
samples	O
clustered	O
into	O
five	O
main	O
groups	O
,	O
each	O
characterized	O
by	O
the	O
expression	O
patterns	O
of	O
four	O
gene	O
clusters	O
that	O
were	O
found	O
to	O
be	O
strongly	O
enriched	O
for	O
specific	O
gene	O
ontologies	O
Figure	O
3a	O
and	O
Additional	O
data	O
file	O
3.In	O
accordance	O
with	O
these	O
data	O
,	O
comparative	O
clinical	O
studies	O
have	O
indicated	O
that	O
aromatase	O
inhibitors	O
blocking	O
estrogen	O
biosynthesis	O
may	O
provide	O
major	O
benefits	O
in	O
respect	O
to	O
ERα	O
antagonists	O
in	O
breast	O
cancer	O
patients	O
46	O
.	O
33	O
,34.Acting	O
through	O
the	O
progesterone	O
receptor	O
,	O
progesterone	O
is	O
the	O
physiological	O
negative	O
regulator	O
of	O
estrogen	O
activation	O
45	O
.	O
Briefly	O
,	O
FoxN1fxfx	O
18	O
mice	O
were	O
crossbred	O
with	O
CMV-promoter-driven	O
CreERT	O
ubiquitous	O
promoter-driven	O
Cre-recombinase	O
and	O
estrogen-receptor	O
fusion	O
protein	O
Tg	O
mice	O
,	O
then	O
with	O
rag-gfp	O
reporter	O
mice.A	O
cell-type-specific	O
functional	O
understanding	O
of	O
molecular	O
alterations	O
will	O
be	O
increasingly	O
important	O
to	O
improve	O
the	O
success	O
of	O
molecular	O
assays	O
in	O
clinical	O
decision-making	O
.	O
Notably	O
,	O
it	O
was	O
reported	O
that	O
disruption	O
of	O
tldD	O
gene	O
in	O
G.	O
oxydans	O
led	O
to	O
a	O
drop	O
of	O
PQQ	O
excretion	O
below	O
the	O
detection	O
limit	O
and	O
a	O
decrease	O
in	O
cell	O
growth	O
,	O
indicating	O
that	O
the	O
related	O
tldD	O
gene	O
was	O
essential	O
for	O
PQQ	O
biosynthesis	O
32.CD	O
,	O
cluster	O
of	O
differentiation	O
;	O
CreERT	O
,	O
ubiquitous	O
promoter-driven	O
Cre-recombinase	O
and	O
estrogen-receptor	O
fusion	O
protein	O
;	O
FC	O
,	O
FoxN1fxfxCreERT	O
;	O
FF	O
,	O
FoxN1fxfx	O
without	O
CreERT	O
for	O
controls	O
;	O
Foxn1	O
,	O
Forkhead	O
box	O
protein	O
N1	O
;	O
FoxN1fxfx	O
or	O
FoxN1-floxed	O
,	O
loxp-flanked	O
FoxN1	O
gene	O
;	O
i.p	O
.	O
To	O
assess	O
this	O
hypothesis	O
,	O
we	O
investigated	O
the	O
association	O
of	O
common	O
genetic	O
variation	O
,	O
using	O
a	O
tagging	O
SNP	O
approach	O
,	O
within	O
60	O
cofactor	O
genes	O
in	O
two	O
large	O
case-control	O
samples	O
of	O
breast	O
cancer	O
from	O
Sweden	O
and	O
Finland	O
,	O
and	O
investigated	O
their	O
interaction	O
with	O
genetic	O
variation	O
within	O
ESR1	O
in	O
terms	O
of	O
influencing	O
the	O
risk	O
of	O
hormone-driven	O
breast	O
cancer.A	O
and	O
B	O
The	O
curves	O
are	O
nonlinear	O
one-phase	O
decay	O
;	O
the	O
results	O
demonstrated	O
that	O
absolute	O
cell	O
numbers	O
of	O
tTreg	O
cells	O
were	O
not	O
reduced	O
with	O
age	O
,	O
while	O
the	O
numbers	O
of	O
tTcon	O
cells	O
were	O
dramatically	O
reduced	O
with	O
age	O
.	O
Two	O
databases	O
were	O
created	O
,	O
one	O
with	O
the	O
results	O
of	O
the	O
CTC	O
analysis	O
,	O
patient	O
ID	O
and	O
inclusion	O
date	O
and	O
one	O
with	O
the	O
clinical	O
data	O
from	O
the	O
patient	O
charts	O
;	O
both	O
were	O
merged	O
at	O
the	O
time	O
of	O
the	O
analysis	O
at	O
the	O
hospital.The	O
final	O
multivariate-adjusted	O
models	O
shown	O
include	O
those	O
factors	O
that	O
either	O
changed	O
the	O
estimated	O
effect	O
by	O
10	O
%	O
or	O
more	O
in	O
a	O
best-fitting	O
model	O
,	O
which	O
was	O
developed	O
by	O
starting	O
with	O
a	O
full	O
model	O
and	O
then	O
excluding	O
covariates	O
that	O
did	O
not	O
improve	O
the	O
overall	O
fit	O
.	O
To	O
determine	O
the	O
consistency	O
of	O
treatment	O
benefit	O
for	O
PFS	O
across	O
both	O
subgroups	O
,	O
the	O
interaction	O
p	O
value	O
was	O
obtained	O
from	O
the	O
stratified	O
Cox	O
proportional	O
hazard	O
model	O
that	O
included	O
treatment	O
,	O
subgroup	O
,	O
and	O
treatment	O
by	O
subgroup	O
interaction	O
terms	O
.	O
In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
SMARCE1	O
plays	O
a	O
key	O
role	O
in	O
breast	O
cancer	O
metastasis	O
by	O
protecting	O
breast	O
cancer	O
cells	O
against	O
anoikis	O
through	O
the	O
HIF1APTK2	O
pathway.Tamoxifen	O
or	O
estrogen	O
withdrawal	O
block	O
this	O
effect	O
and	O
increase	O
the	O
dependence	O
of	O
breast	O
cancer	O
cells	O
on	O
Notch	O
signalling	O
10	O
.	O
,	O
prior	O
hormonal	O
therapy	O
status	O
,	O
prior	O
neoadjuvant	O
chemotherapy	O
status	O
,	O
de	O
novo	O
disease	O
status	O
,	O
race	O
,	O
estrogenprogesterone	O
receptor	O
status	O
,	O
and	O
selected	O
biomarkers.Ncoa4	O
nuclear	O
receptor	O
co-activator	O
4	O
and	O
FOXA1	O
forkhead-box	O
A1	O
,	O
both	O
have	O
been	O
shown	O
to	O
act	O
as	O
transcriptional	O
activators	O
of	O
estrogen	O
ER-α	O
36	O
,37	O
.	O
Finally	O
,	O
while	O
our	O
experimental	O
results	O
were	O
derived	O
largely	O
with	O
aggressive	O
breast	O
cancer	O
cell	O
lines	O
that	O
do	O
not	O
express	O
estrogen	O
or	O
progesterone	O
receptors	O
,	O
we	O
found	O
that	O
the	O
expression	O
pattern	O
of	O
Tiam1	O
and	O
OPN	O
in	O
human	O
breast	O
cancer-associated	O
fibroblasts	O
was	O
correlated	O
with	O
invasiveness	O
rather	O
than	O
hormone	O
receptor	O
expression.Correlations	O
were	O
done	O
with	O
Spearman	O
's	O
rank	O
correlation	O
in	O
InStat	O
.	O
,	O
estrogen	O
ER	O
,	O
progesterone	O
PR	O
and	O
human	O
epidermal	O
growth	O
factor	O
receptor-2	O
HER2.DEFS	O
,	O
distant	O
event-free	O
survival	O
;	O
MKS	O
,	O
mitotic	O
kinase	O
score	O
;	O
ERS	O
,	O
estrogen-related	O
score	O
;	O
GGI	O
,	O
genomic	O
grade	O
index	O
;	O
Lum	O
,	O
luminal	O
;	O
ER+HER2-lowP	O
,	O
ER-positivehuman	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
HER2-negative	O
low	O
proliferation	O
;	O
ER+HER2-highP	O
,	O
ER-positiveHER2-negative	O
high	O
proliferation	O
;	O
NA	O
,	O
not	O
applicable	O
.	O
Correlation	O
between	O
averaged	O
estrogen	O
I	O
and	O
progesterone	O
J	O
receptor	O
levels	O
in	O
cores	O
ERSPR	O
positive	O
=	O
1	O
and	O
ERSPR	O
negative	O
=	O
0	O
correlated	O
with	O
PrP	O
scores.Overall	O
,	O
this	O
means	O
that	O
for	O
receptor-negative	O
breast	O
cancers	O
,	O
current	O
explanations	O
based	O
on	O
estrogen	O
and	O
progesterone	O
actions	O
and	O
receptors	O
are	O
inadequate	O
,	O
and	O
the	O
related	O
hormone-based	O
therapies	O
are	O
ineffective	O
.	O
Accordingly	O
,	O
HER44ICD	O
forms	O
a	O
complex	O
with	O
ER	O
and	O
is	O
translocated	O
into	O
the	O
nucleus	O
upon	O
estrogen	O
stimulus	O
,	O
and	O
the	O
nuclear	O
ER4ICD	O
complex	O
co-activates	O
ER	O
transcription	O
by	O
being	O
selectively	O
recruited	O
to	O
estrogen	O
responsive	O
gene	O
promoters	O
such	O
as	O
progesterone	O
receptor	O
PgR	O
14	O
,21.In	O
a	O
study	O
following	O
the	O
influence	O
of	O
ERβ	O
on	O
ERα	O
transcription	O
,	O
a	O
model	O
of	O
estrogen	O
positive	O
T47D	O
cell	O
line	O
containing	O
a	O
tet-off	O
inducible	O
FLAG-ERβ	O
corresponding	O
to	O
the	O
short	O
ERβ1	O
isoform	O
was	O
used	O
23	O
.	O
Prediction	O
analysis	O
of	O
microarray	O
50	O
PAM50	O
was	O
used	O
to	O
classify	O
breast	O
cancer	O
molecular	O
subtypes	O
within	O
the	O
TCC	O
dataset	O
11.AIs	O
work	O
by	O
abrogating	O
the	O
activity	O
of	O
the	O
enzyme	O
aromatase	O
Cyp	O
19	O
,	O
which	O
converts	O
circulating	O
androgens	O
into	O
estrogen	O
within	O
different	O
body	O
compartments	O
including	O
mammary	O
adipose	O
tissue	O
2–4	O
.	O
To	O
directly	O
address	O
the	O
role	O
of	O
fork-associated	O
chromatin	O
proteins	O
in	O
histone	O
spreading	O
at	O
replication	O
,	O
we	O
examined	O
mutations	O
of	O
PCNA	O
and	O
Chromatin	O
Assembly	O
Factor	O
CAF-1	O
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
replication-coupled	O
histone	O
deposition	O
48	O
,49.Each	O
BC	O
subtype	O
,	O
including	O
the	O
luminal	O
A-like	O
,	O
luminal	O
B-like	O
,	O
luminal	O
HER2-like	O
,	O
HER2-like	O
and	O
triple	O
negative	O
breast	O
cancer	O
TNBC	O
,	O
presents	O
with	O
different	O
age	O
and	O
risk	O
factor	O
distributions	O
2	O
.	O
The	O
mutation	O
was	O
found	O
to	O
be	O
associated	O
with	O
breast	O
cancer	O
with	O
an	O
odds	O
ratio	O
OR	O
of	O
1.86	O
95	O
%	O
confidence	O
interval	O
CI	O
1.26–2.75	O
,	O
P	O
=	O
0.0018	O
,	O
especially	O
among	O
triple-negative	O
breast	O
cancer	O
TNBC	O
;	O
estrogen	O
ER	O
and	O
progesterone	O
PR	O
receptor	O
and	O
HER2	O
negative	O
cases	O
OR	O
3.56	O
,	O
95	O
%	O
CI	O
1.81–6.98	O
,	O
P	O
=	O
0.0002.When	O
gene	O
expression	O
analysis	O
of	O
MCF7	O
cells	O
in	O
hormone-depleted	O
medium	O
was	O
performed	O
following	O
transfection	O
with	O
the	O
mutant	O
ESR1	O
constructs	O
with	O
the	O
highest	O
constitutive	O
activity	O
Y537S	O
,	O
D538G	O
and	O
S463PD538G	O
,	O
the	O
mutants	O
demonstrated	O
a	O
unique	O
and	O
shared	O
gene	O
expression	O
pattern	O
that	O
was	O
distinct	O
from	O
the	O
wild-type	O
receptor	O
.	O
Although	O
neither	O
estrogen	O
nor	O
progesterone	O
receptor	O
status	O
were	O
significantly	O
associated	O
with	O
RPMM	O
methylation	O
profiles	O
,	O
large	O
numbers	O
of	O
specific	O
CpG	O
loci	O
had	O
significant	O
methylation	O
associations	O
with	O
these	O
tumor	O
characteristics	O
in	O
locus-by-locus	O
analysis	O
Table	O
S2	O
and	O
Table	O
S3.For	O
individuals	O
in	O
whom	O
tumor	O
tissue	O
was	O
available	O
for	O
PTEN	O
staining	O
,	O
upward	O
+1	O
and	O
downward	O
-1	O
adjustments	O
were	O
made	O
for	O
the	O
absence	O
or	O
presence	O
of	O
PTEN	O
staining	O
,	O
respectively	O
.	O
Other	O
pre-specified	O
subanalyses	O
were	O
carried	O
out	O
according	O
to	O
ECOG	O
performance	O
status	O
,	O
baseline	O
metastatic	O
sites	O
liver	O
,	O
lung	O
,	O
bone	O
,	O
etc.These	O
studies	O
have	O
shown	O
that	O
Tyr537	O
hydrogen	O
bonds	O
with	O
Asn348	O
in	O
the	O
wild-type	O
receptor	O
,	O
resulting	O
in	O
stabilization	O
of	O
the	O
backbone	O
of	O
the	O
helix	O
11–12	O
loop	O
and	O
leaving	O
Leu536	O
in	O
a	O
solvent-exposed	O
position	O
.	O
Significantly	O
,	O
cyclin	O
D1	O
plays	O
an	O
important	O
role	O
in	O
the	O
progression	O
through	O
the	O
cell	O
cycle	O
induced	O
by	O
estrogen	O
and	O
ER	O
29.Interestingly	O
,	O
as	O
shown	O
in	O
Figure	O
4	O
,	O
treatment	O
of	O
MCF-7	O
cells	O
with	O
the	O
selective	O
estrogen-receptor	O
modulator	O
SERM	O
tamoxifen	O
caused	O
repression	O
of	O
Hes-6	O
,	O
indicating	O
that	O
Hes-6	O
might	O
work	O
as	O
a	O
marker	O
for	O
tamoxifen	O
response	O
in	O
breast	O
cancer	O
cells	O
.	O
,	O
intraperitoneally	O
;	O
i.t	O
.	O
In	O
the	O
17	O
false-negative	O
patients	O
,	O
15	O
had	O
>	O
50	O
%	O
estrogen-receptor-positive	O
cells	O
,	O
and	O
13	O
also	O
had	O
>	O
20	O
%	O
progesterone-receptor-positive	O
cells	O
in	O
primary	O
tumors.Genomic	O
amplification	O
of	O
BAF57SMARCE1	O
,	O
a	O
core	O
subunit	O
of	O
human	O
SWISNF	O
complexes	O
that	O
plays	O
a	O
role	O
in	O
interaction	O
with	O
transcription	O
factors	O
and	O
chromatin	O
,	O
has	O
been	O
linked	O
to	O
high	O
risk	O
of	O
recurrence	O
of	O
estrogenprogesterone	O
receptor-negative	O
breast	O
tumors	O
12	O
.	O
Staining	O
was	O
also	O
performed	O
in	O
all	O
tumors	O
for	O
ER	O
,	O
progesterone	O
receptor	O
PR	O
,	O
and	O
Her2	O
amplification.It	O
is	O
possible	O
that	O
more	O
complex	O
mechanism	O
underlies	O
our	O
model	O
,	O
but	O
it	O
is	O
still	O
unequivocal	O
that	O
COUP-TFII	O
has	O
access	O
to	O
the	O
principal	O
part	O
of	O
steroid	O
receptor	O
regulation	O
in	O
the	O
uterine	O
biology	O
.	O
Moreover	O
,	O
it	O
has	O
previously	O
been	O
shown	O
,	O
in	O
this	O
system	O
,	O
that	O
estradiol	O
inhibits	O
Notch	O
activity	O
by	O
altering	O
Notch	O
receptor	O
cellular	O
localization.As	O
it	O
concerns	O
the	O
pesticide	O
atrazine	O
,	O
it	O
exerted	O
estrogenic	O
effects	O
without	O
binding	O
to	O
ERs	O
61	O
and	O
exhibiting	O
the	O
capability	O
to	O
activate	O
the	O
GPER-mediated	O
pathway	O
despite	O
a	O
low	O
binding	O
affinity	O
for	O
this	O
receptor	O
25	O
,27	O
.	O
,	O
estrogen	O
and	O
progesterone	O
receptor	O
status	O
;	O
therefore	O
,	O
subtype	O
analyses	O
were	O
not	O
performed	O
at	O
this	O
stage	O
.	O
These	O
structural	O
studies	O
also	O
support	O
the	O
notion	O
that	O
ESR1	O
mutations	O
probably	O
arose	O
in	O
response	O
to	O
an	O
estrogen-deprived	O
state	O
rather	O
than	O
anti-estrogen	O
therapy	O
22	O
.	O
Interestingly	O
,	O
as	O
shown	O
in	O
Figure	O
4	O
,	O
treatment	O
of	O
MCF-7	O
cells	O
with	O
the	O
selective	O
estrogen-receptor	O
modulator	O
SERM	O
tamoxifen	O
caused	O
repression	O
of	O
Hes-6	O
,	O
indicating	O
that	O
Hes-6	O
might	O
work	O
as	O
a	O
marker	O
for	O
tamoxifen	O
response	O
in	O
breast	O
cancer	O
cells.Not	O
surprisingly	O
,	O
molecular	O
classification	O
and	O
current	O
prognostic	O
signatures	O
mainly	O
reflect	O
these	O
molecular	O
features	O
2	O
.	O
Furthermore	O
,	O
it	O
has	O
been	O
hypothesized	O
that	O
hormone-related	O
risk	O
factors	O
that	O
reflect	O
exposure	O
to	O
estrogen	O
and	O
progesterone	O
may	O
be	O
predominantly	O
associated	O
with	O
breast	O
tumors	O
that	O
express	O
ER	O
and	O
PR	O
,	O
but	O
not	O
with	O
those	O
lacking	O
ER	O
and	O
PR	O
expression	O
8-14.The	O
TldD	O
protein	O
of	O
G.	O
oxydans	O
621H	O
,	O
related	O
to	O
the	O
E.	O
coli	O
TldD	O
,	O
is	O
a	O
peptidase	O
involved	O
in	O
processing	O
of	O
small	O
peptides	O
.	O
Given	O
the	O
modification	O
of	O
ER	O
activity	O
by	O
its	O
cofactors	O
through	O
their	O
physical	O
and	O
functional	O
interactions	O
16	O
,	O
the	O
cofactor	O
proteins	O
that	O
bind	O
to	O
ER	O
may	O
be	O
as	O
important	O
as	O
the	O
receptor	O
itself	O
in	O
mediating	O
transcriptional	O
response	O
to	O
estrogen	O
exposure	O
17.CreERT	O
,	O
ubiquitous	O
promoter-driven	O
Cre-recombinase	O
and	O
estrogen-receptor	O
fusion	O
protein	O
;	O
FoxN1fxfx	O
,	O
loxp-flanked	O
FoxN1	O
gene	O
;	O
Tcon	O
,	O
conventional	O
T	O
cell	O
;	O
tTcon	O
,	O
thymic	O
conventional	O
T	O
cell	O
;	O
tTreg	O
,	O
thymic	O
regulatory	O
T	O
cell	O
.	O
The	O
impairment	O
of	O
the	O
TrxTrxR	O
system	O
has	O
thus	O
been	O
described	O
to	O
increase	O
the	O
progesterone	O
receptor	O
expression	O
in	O
MCF-7	O
cells	O
in	O
response	O
to	O
estrogen	O
30.A	O
matching	O
control	O
cell	O
line	O
,	O
HCC1954BL	O
,	O
which	O
was	O
established	O
from	O
lymphoblast	O
cells	O
of	O
the	O
same	O
patient	O
,	O
was	O
studied	O
in	O
parallel	O
.	O
To	O
determine	O
whether	O
the	O
capacity	O
of	O
newly	O
generated	O
tTreg	O
cells	O
is	O
impaired	O
in	O
aged	O
thymus	O
17	O
andor	O
in	O
the	O
TEC	O
defect-induced	O
atrophied	O
thymus	O
,	O
we	O
utilized	O
our	O
previously	O
generated	O
mouse	O
model	O
with	O
accelerated	O
thymic	O
atrophy	O
due	O
to	O
postnatal	O
TEC	O
homeostatic	O
defect	O
12	O
,	O
in	O
which	O
the	O
loxp-flanked	O
FoxN1	O
gene	O
FoxN1fxfx	O
18	O
can	O
be	O
deleted	O
by	O
ubiquitous	O
promoter-driven	O
Cre-recombinase	O
and	O
estrogen-receptor	O
fusion	O
protein	O
CreERT	O
mediation	O
through	O
either	O
a	O
tamoxifen	O
TM	O
induction	O
or	O
a	O
CreERT	O
autoleakage	O
with	O
age.These	O
preclinical	O
studies	O
indicate	O
that	O
HER4	O
contributes	O
to	O
ER	O
translocation	O
to	O
target	O
genes	O
and	O
functions	O
as	O
an	O
ER	O
transcriptional	O
co-regulator	O
,	O
selectively	O
binding	O
with	O
ER	O
to	O
gene	O
promoters	O
harboring	O
ERE	O
.	O
All	O
variants	O
were	O
hypothesized	O
to	O
result	O
in	O
decreased	O
enzyme	O
function	O
10.Supporting	O
these	O
results	O
,	O
analysis	O
of	O
the	O
mRNA	O
microarray	O
data	O
52-54	O
indicated	O
that	O
in	O
two	O
of	O
three	O
studies	O
,	O
high-BiP	O
expressing	O
tumors	O
were	O
associated	O
with	O
higher	O
PrP	O
mRNA	O
levels	O
Table	O
2	O
.	O
In	O
recent	O
years	O
,	O
the	O
genome-wide	O
search	O
for	O
markers	O
predicting	O
prognosis	O
in	O
breast	O
cancer	O
has	O
led	O
to	O
a	O
global	O
picture	O
in	O
which	O
three	O
coordinates	O
representing	O
important	O
biological	O
processes	O
have	O
outstanding	O
prognostic	O
consequences	O
31	O
,35	O
,36	O
:	O
the	O
proliferation	O
metagene	O
,	O
consisting	O
of	O
a	O
group	O
of	O
genes	O
indicating	O
transition	O
from	O
slow	O
to	O
fast	O
proliferation	O
;	O
the	O
B-cell	O
and	O
T-cell	O
metagenes	O
as	O
markers	O
for	O
immune	O
cell	O
infiltration	O
;	O
and	O
estrogen-receptor-dependent	O
genes.Metaphase	O
FISH	O
indicated	O
that	O
both	O
alleles	O
of	O
these	O
genes	O
reside	O
on	O
normal-looking	O
chromosomes	O
11	O
in	O
MCF-7	O
cells	O
Figure	O
4A	O
.	O
One	O
of	O
the	O
major	O
advances	O
in	O
breast	O
cancer	O
therapy	O
in	O
the	O
past	O
decade	O
has	O
been	O
the	O
widespread	O
endorsement	O
of	O
aromatase	O
inhibitors	O
AIs	O
as	O
first-line	O
therapy	O
for	O
postmenopausal	O
patients	O
with	O
hormone	O
receptor-positive	O
breast	O
cancer.The	O
discrepancy	O
between	O
these	O
results	O
and	O
those	O
from	O
observational	O
studies	O
is	O
puzzling	O
.	O
Consistent	O
with	O
clinical	O
outcomes	O
,	O
quantitative	O
proteomic	O
analysis	O
of	O
acquired	O
tamoxifen	O
resistance	O
cells	O
confirmed	O
signatures	O
associated	O
with	O
an	O
increased	O
migratory	O
capacity	O
4.We	O
chose	O
to	O
limit	O
our	O
candidate	O
gene	O
pool	O
to	O
minimize	O
the	O
risk	O
of	O
false-positive	O
results	O
.	O
Worldwide	O
,	O
breast	O
cancer	O
BC	O
is	O
the	O
most	O
frequently	O
diagnosed	O
malignancy	O
and	O
leading	O
cause	O
of	O
female	O
cancer	O
death	O
1.The	O
experiments	O
of	O
ESR1	O
gene	O
silencing	O
confirmed	O
that	O
the	O
expression	O
of	O
ERα	O
is	O
required	O
for	O
moderate	O
nitrosative	O
stress	O
to	O
increase	O
the	O
proliferative	O
capacity	O
of	O
breast	O
cancer	O
cells	O
.	O
Patients	O
with	O
receptor-negative	O
tumors	O
generally	O
show	O
lack	O
of	O
response	O
to	O
adjuvant	O
hormone	O
therapy	O
and	O
have	O
significantly	O
higher	O
risk	O
of	O
mortality	O
compared	O
with	O
patients	O
with	O
tumors	O
that	O
are	O
ER	O
andor	O
PR	O
positive	O
10-14.This	O
cell	O
line	O
,	O
derived	O
from	O
a	O
ductal	O
breast	O
carcinoma	O
,	O
is	O
estrogen	O
negative	O
,	O
progesterone	O
receptor	O
negative	O
and	O
ERBB2	O
positive	O
,	O
and	O
has	O
been	O
particularly	O
well	O
studied	O
at	O
the	O
molecular	O
level	O
2	O
,7	O
,23	O
.	O
In	O
contrast	O
,	O
no	O
significant	O
correlation	O
was	O
observed	O
between	O
the	O
levels	O
of	O
BiP	O
and	O
the	O
estrogen	O
and	O
progesterone	O
receptor	O
status.Several	O
epidemiological	O
studies	O
have	O
examined	O
this	O
hypothesis	O
by	O
ER	O
and	O
PR	O
status	O
separately	O
or	O
jointly	O
15-17	O
,	O
and	O
a	O
review	O
from	O
2004	O
17	O
concluded	O
that	O
early	O
age	O
at	O
menarche	O
,	O
nulliparity	O
,	O
and	O
delayed	O
childbearing	O
were	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
receptor-positive	O
breast	O
cancer	O
,	O
but	O
not	O
with	O
receptor-negative	O
breast	O
cancer	O
.	O
Both	O
heterozygotes	O
and	O
homozygotes	O
were	O
assessed	O
separately	O
in	O
relation	O
to	O
the	O
referent.Data	O
analyses	O
of	O
three	O
publically	O
available	O
breast	O
cancer	O
mRNA	O
microarray	O
databases	O
52-54	O
revealed	O
that	O
higher	O
PrP	O
mRNA	O
levels	O
were	O
significantly	O
associated	O
with	O
lower	O
estrogen	O
ERS	O
and	O
progesterone	O
PR	O
receptor	O
levels	O
and	O
higher	O
tumor	O
grades	O
Table	O
1	O
.	O
Since	O
its	O
identification	O
to	O
date	O
,	O
the	O
transduction	O
signaling	O
and	O
gene	O
expression	O
profile	O
triggered	O
by	O
GPER	O
have	O
been	O
extensively	O
characterized.Consistent	O
with	O
a	O
predicted	O
induction	O
of	O
DNA	O
damage	O
,	O
doxorubicin-treated	O
organotypic	O
cultures	O
exhibited	O
high	O
levels	O
of	O
phosphorylated	O
histone	O
H2AX	O
γH2AX	O
,	O
a	O
cellular	O
marker	O
of	O
double-strand	O
DNA	O
breaks	O
DSB	O
Figure	O
1B	O
,	O
compared	O
to	O
vehicle-treated	O
cultures	O
or	O
tumors	O
harvested	O
at	O
baseline	O
conditions	O
Figure	O
1C	O
.	O
Bag-1	O
also	O
has	O
anti-apoptotic	O
effects	O
that	O
are	O
independent	O
of	O
Bcl-2	O
;	O
it	O
binds	O
to	O
multiple	O
receptor	O
tyrosine	O
kinases	O
and	O
enhances	O
their	O
ability	O
to	O
inhibit	O
apoptosis	O
44	O
,	O
and	O
it	O
interacts	O
with	O
the	O
heat	O
shock	O
proteins	O
HSC70	O
and	O
HSP70	O
45.Three	O
different	O
mutants	O
of	O
PCNA	O
that	O
disrupt	O
interactions	O
with	O
replication	O
proteins	O
or	O
with	O
replication-coupled	O
chromatin-assembly	O
factors	O
showed	O
only	O
minor	O
effects	O
on	O
5′	O
retention	O
of	O
ancestral	O
H3	O
at	O
target	O
genes	O
SPA2	O
and	O
BUD3	O
Figure	O
S8C	O
.	O
The	O
only	O
randomized	O
controlled	O
trial	O
comparing	O
estrogen–progestin	O
therapy	O
with	O
placebo	O
therapy	O
found	O
women	O
in	O
the	O
treated	O
arm	O
to	O
have	O
slightly	O
larger	O
tumors	O
with	O
a	O
higher	O
proportion	O
of	O
lymph	O
node	O
involvement	O
compared	O
with	O
those	O
in	O
the	O
untreated	O
arm	O
2.The	O
most	O
profound	O
effects	O
on	O
gene	O
expression	O
profiles	O
in	O
breast	O
cancer	O
are	O
related	O
to	O
estrogen	O
ER	O
,	O
and	O
proliferation	O
status	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
to	O
Human	O
Epidermal	O
Growth	O
Factor	O
Receptor	O
2	O
HER2	O
status	O
.	O
In	O
brief	O
,	O
this	O
system	O
assigns	O
scores	O
depending	O
on	O
the	O
type	O
of	O
cancer	O
and	O
age	O
at	O
diagnosis	O
and	O
developed	O
such	O
that	O
a	O
score	O
of	O
15	O
was	O
equivalent	O
to	O
a	O
10	O
%	O
chance	O
of	O
identifying	O
a	O
BRCA1	O
or	O
BRCA2	O
mutation.Data	O
on	O
estrogen	O
and	O
progesterone	O
receptor	O
status	O
and	O
ERBB2	O
expression	O
were	O
obtained	O
from	O
the	O
KPNC	O
Cancer	O
Registry	O
37	O
.	O
To	O
understand	O
whether	O
TXNRD1	O
and	O
TXNIP	O
are	O
independent	O
of	O
conventional	O
clinical	O
parameters	O
,	O
we	O
performed	O
a	O
multivariate	O
Cox	O
analysis	O
Table	O
3.Risk	O
assessment	O
is	O
of	O
utmost	O
importance	O
because	O
of	O
the	O
well-known	O
side	O
effects	O
of	O
adjuvant	O
treatment	O
and	O
is	O
being	O
conducted	O
by	O
means	O
of	O
TNM	O
classification	O
and	O
differentiation	O
grade	O
complemented	O
by	O
estrogen	O
and	O
progesterone	O
receptor	O
status	O
,	O
Her2neu	O
expression	O
and	O
peritumoral	O
vascular	O
invasion	O
2-6	O
.	O
Underlying	O
data	O
used	O
in	O
the	O
generation	O
of	O
this	O
figure	O
can	O
be	O
found	O
in	O
S1	O
Data.Compared	O
to	O
the	O
overall	O
population	O
of	O
women	O
diagnosed	O
with	O
breast	O
cancer	O
in	O
the	O
Kiaser	O
Permanente	O
Northern	O
California	O
cancer	O
registry	O
from	O
200–2009	O
,	O
this	O
surgical	O
cohort	O
has	O
a	O
higher	O
prevalence	O
of	O
hormone	O
receptor	O
positivity	O
78	O
%	O
overall	O
vs.	O
88	O
%	O
here	O
,	O
particularly	O
among	O
pre-menopausal	O
women	O
's	O
tumors	O
74	O
%	O
overall	O
vs.	O
95	O
%	O
here	O
.	O
N	O
,	O
number	O
of	O
patients	O
;	O
MKS	O
,	O
mitotic	O
kinase	O
score	O
;	O
ERS	O
,	O
estrogen-related	O
score	O
;	O
HER2	O
:	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2.Breast	O
cancer	O
detection	O
methods	O
were	O
recorded	O
at	O
time	O
of	O
diagnosis	O
from	O
the	O
chart	O
notes	O
and	O
were	O
the	O
following	O
:	O
1	O
patient	O
detected	O
:	O
lump	O
or	O
abnormality	O
discovered	O
by	O
the	O
patient	O
symptomatic	O
;	O
2	O
physician	O
detected	O
:	O
lump	O
or	O
abnormality	O
discovered	O
during	O
routine	O
physical	O
examination	O
symptomatic	O
;	O
or	O
3	O
mammography	O
detected	O
:	O
lump	O
or	O
breast	O
abnormality	O
discovered	O
by	O
a	O
non-diagnostic	O
mammogram	O
.	O
Of	O
note	O
,	O
genotyping	O
for	O
CYP2D6*4	O
was	O
included	O
to	O
account	O
for	O
any	O
possible	O
differential	O
effect	O
of	O
variable	O
tamoxifen	O
metabolism	O
on	O
outcome	O
among	O
patients	O
whose	O
tumors	O
were	O
estrogen-receptor	O
positive.CreERT	O
,	O
ubiquitous	O
promoter-driven	O
Cre-recombinase	O
and	O
estrogen-receptor	O
fusion	O
protein	O
;	O
FC	O
,	O
FoxN1fxfxCreERT	O
;	O
FF	O
,	O
FoxN1fxfx	O
without	O
CreERT	O
for	O
controls	O
;	O
Foxn1	O
,	O
Forkhead	O
box	O
protein	O
N1	O
;	O
FoxN1fxfx	O
,	O
loxp-flanked	O
FoxN1	O
gene	O
;	O
GFP	O
,	O
green	O
fluorescent	O
protein	O
;	O
Tcon	O
,	O
conventional	O
T	O
cell	O
;	O
TM	O
,	O
tamoxifen	O
;	O
tTcon	O
,	O
thymic	O
conventional	O
T	O
cell	O
;	O
tTreg	O
,	O
thymic	O
regulatory	O
T	O
cell	O
.	O
The	O
TldD	O
protein	O
of	O
G.	O
oxydans	O
621H	O
,	O
related	O
to	O
the	O
E.	O
coli	O
TldD	O
,	O
is	O
a	O
peptidase	O
involved	O
in	O
processing	O
of	O
small	O
peptides.This	O
is	O
exemplified	O
by	O
the	O
advent	O
of	O
therapeutic	O
agents	O
targeting	O
estrogen-receptor	O
positive	O
ER+	O
and	O
HER2-positive	O
HER2+	O
breast	O
cancers	O
,	O
which	O
make	O
up	O
approximately	O
70	O
%	O
of	O
all	O
breast	O
tumours	O
2	O
,3	O
.	O
P-values	O
in	O
boldface	O
were	O
statistically	O
significant	O
at	O
P	O
<	O
0.05.We	O
selected	O
15	O
SNPs	O
CYP2B6*4	O
,	O
CYP2B6*5	O
,	O
CYP2B6*6	O
,	O
CYP2B6*7	O
,	O
CYP2B6*9	O
,	O
CYP2C9*2	O
,	O
CYP2C9*3	O
,	O
CYP3A4*1B	O
,	O
CYP3A5*3	O
,	O
CYP3A5*6	O
,	O
CYP2D6*4	O
,	O
GSTM1	O
,	O
GSTT1	O
,	O
GSTP1*B	O
,	O
GSTP1*C	O
in	O
eight	O
genes	O
for	O
inclusion	O
by	O
first	O
identifying	O
cyclophosphamide-metabolizing	O
enzyme	O
polymorphisms	O
that	O
were	O
associated	O
with	O
functional	O
effects	O
on	O
enzyme	O
expression	O
,	O
levels	O
or	O
activity	O
,	O
then	O
excluding	O
those	O
in	O
which	O
the	O
expected	O
prevalence	O
of	O
the	O
combination	O
of	O
alleles	O
for	O
a	O
particular	O
gene	O
was	O
≤	O
10	O
%	O
of	O
the	O
general	O
population	O
,	O
since	O
these	O
constituted	O
a	O
minute	O
fraction	O
of	O
cyclophosphamide	O
metabolism	O
and	O
significant	O
effects	O
for	O
these	O
SNPs	O
were	O
unlikely	O
to	O
be	O
detectable	O
with	O
the	O
sample	O
size	O
available	O
.	O
For	O
instance	O
,	O
the	O
phytoestrogen	O
genistein	O
and	O
the	O
xenoestrogen	O
bisphenol	O
A	O
,	O
which	O
exert	O
estrogen-like	O
activities	O
binding	O
to	O
and	O
activating	O
ERα	O
9	O
,59	O
,	O
displayed	O
the	O
ability	O
to	O
bind	O
to	O
and	O
activate	O
GPER	O
signaling	O
9	O
,27	O
,60.Our	O
analysis	O
of	O
publicly	O
available	O
cDNA	O
arrays	O
from	O
Gruvberger	O
et	O
al	O
.	O
Moreover	O
,	O
the	O
existence	O
of	O
alternative	O
ERs	O
able	O
to	O
mediate	O
estrogen	O
signaling	O
without	O
exhibiting	O
any	O
sensitivity	O
to	O
the	O
repressive	O
action	O
of	O
the	O
ER	O
antagonists	O
could	O
be	O
also	O
involved	O
in	O
the	O
resistance	O
to	O
endocrine	O
agents.Over	O
the	O
past	O
decade	O
,	O
it	O
has	O
become	O
evident	O
that	O
BC	O
represents	O
a	O
heterogeneous	O
disease	O
,	O
for	O
which	O
different	O
subtypes	O
can	O
be	O
distinguished	O
based	O
on	O
the	O
combination	O
of	O
tumor	O
grade	O
and	O
the	O
presence	O
of	O
hormone	O
receptors	O
,	O
i.e	O
.	O
Our	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
alcohol	O
exerts	O
its	O
effect	O
on	O
the	O
premenopausal	O
breast	O
via	O
estrogen.In	O
order	O
to	O
understand	O
the	O
role	O
of	O
TXNRD1	O
and	O
TXNIP	O
,	O
we	O
determined	O
their	O
relation	O
to	O
these	O
three	O
coordinates	O
according	O
to	O
Freis	O
and	O
colleagues	O
37	O
.	O
For	O
all	O
breast	O
surgical	O
specimens	O
,	O
hormone	O
receptor	O
status	O
and	O
ERBB2	O
expression	O
is	O
routinely	O
determined	O
by	O
IHC	O
at	O
the	O
KPNC	O
regional	O
IHC	O
lab	O
,	O
and	O
if	O
the	O
IHC	O
staining	O
for	O
ERBB2	O
expression	O
is	O
equivocal	O
less	O
than	O
30	O
%	O
strong	O
staining	O
,	O
but	O
more	O
than	O
10	O
%	O
weak	O
staining	O
,	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
at	O
the	O
KPNC	O
regional	O
cytogenetics	O
lab.According	O
to	O
the	O
ExAC	O
15	O
database	O
this	O
mutation	O
is	O
more	O
common	O
in	O
Finland	O
carrier	O
frequency	O
~1.8	O
%	O
than	O
in	O
other	O
European	O
populations	O
carrier	O
frequency	O
~0.3	O
%	O
.	O
Unfortunately	O
,	O
both	O
hir	O
and	O
asf1	O
mutants	O
are	O
lethal	O
in	O
our	O
strain	O
background	O
likely	O
because	O
our	O
strain	O
carries	O
only	O
one	O
copy	O
of	O
the	O
H3H4	O
gene	O
pair	O
51	O
,	O
preventing	O
us	O
from	O
testing	O
this	O
hypothesis.This	O
subtype	O
is	O
therefore	O
similar	O
to	O
the	O
apocrine	O
subclass	O
,	O
recently	O
proposed	O
24	O
,25	O
,	O
which	O
is	O
characterized	O
by	O
over-expression	O
of	O
AR	O
and	O
genes	O
that	O
are	O
either	O
direct	O
targets	O
of	O
ER	O
or	O
responsive	O
to	O
estrogen	O
24	O
,25	O
.	O
In	O
contrast	O
,	O
administration	O
of	O
vehicle	O
had	O
no	O
effect	O
on	O
tumor	O
cell	O
proliferation	O
in	O
these	O
settings	O
Figure	O
1A.We	O
therefore	O
hypothesized	O
that	O
genetic	O
variation	O
within	O
ER	O
cofactor	O
genes	O
may	O
alter	O
cellular	O
response	O
to	O
estrogen	O
exposure	O
and	O
consequently	O
,	O
alone	O
or	O
by	O
interacting	O
with	O
genetic	O
variations	O
within	O
ESR1	O
,	O
modify	O
breast	O
cancer	O
risk	O
in	O
an	O
ER	O
status-dependent	O
fashion	O
.	O
Underlying	O
data	O
used	O
in	O
the	O
generation	O
of	O
this	O
figure	O
panel	O
B	O
can	O
be	O
found	O
in	O
S1	O
Data.The	O
structural	O
basis	O
for	O
constitutive	O
activity	O
of	O
other	O
mutant	O
ER	O
proteins	O
is	O
less	O
well	O
understood	O
although	O
biochemical	O
characterization	O
of	O
some	O
of	O
these	O
mutant	O
proteins	O
has	O
been	O
described	O
36-39	O
.	O
To	O
determine	O
whether	O
the	O
absence	O
of	O
nuclear	O
colocalisation	O
between	O
TFF1	O
and	O
GREB1	O
was	O
an	O
exception	O
or	O
a	O
more	O
general	O
feature	O
of	O
estrogen	O
induced	O
transcription	O
,	O
we	O
analysed	O
the	O
positioning	O
of	O
the	O
progesterone	O
receptor	O
PGR	O
and	O
Cathepsin-D	O
CTSD	O
genes	O
,	O
both	O
located	O
on	O
different	O
regions	O
of	O
chromosome	O
11.These	O
structural	O
OFT	O
defects	O
are	O
presaged	O
by	O
the	O
complete	O
absence	O
of	O
detectable	O
Semaphorin	O
3c	O
Sema3c	O
expression	O
in	O
Twist1	O
;	O
Wnt1-Cre	O
CKO	O
cNCCs	O
Figure	O
S6	O
.	O
Underlying	O
data	O
used	O
in	O
the	O
generation	O
of	O
this	O
figure	O
can	O
be	O
found	O
in	O
S1	O
Data.Additional	O
data	O
file	O
2	O
is	O
based	O
on	O
a	O
dataset	O
from	O
a	O
publicly	O
available	O
lung	O
cancer	O
study	O
of	O
Bhattacharjee	O
et	O
al	O
.	O
According	O
to	O
the	O
authors	O
,	O
no	O
oscillatory	O
recruitment	O
was	O
observed	O
for	O
either	O
receptor	O
subtype	O
whose	O
kinetics	O
of	O
recruitment	O
were	O
similar	O
during	O
the	O
time	O
course	O
analyzed.Finally	O
,	O
while	O
our	O
experimental	O
results	O
were	O
derived	O
largely	O
with	O
aggressive	O
breast	O
cancer	O
cell	O
lines	O
that	O
do	O
not	O
express	O
estrogen	O
or	O
progesterone	O
receptors	O
,	O
we	O
found	O
that	O
the	O
expression	O
pattern	O
of	O
Tiam1	O
and	O
OPN	O
in	O
human	O
breast	O
cancer-associated	O
fibroblasts	O
was	O
correlated	O
with	O
invasiveness	O
rather	O
than	O
hormone	O
receptor	O
expression	O
.	O
CreERT	O
,	O
ubiquitous	O
promoter-driven	O
Cre-recombinase	O
and	O
estrogen-receptor	O
fusion	O
protein	O
;	O
FoxN1fxfx	O
,	O
loxp-flanked	O
FoxN1	O
gene	O
;	O
Tcon	O
,	O
conventional	O
T	O
cell	O
;	O
tTcon	O
,	O
thymic	O
conventional	O
T	O
cell	O
;	O
tTreg	O
,	O
thymic	O
regulatory	O
T	O
cell.The	O
strong	O
stimulation	O
of	O
ERα	O
171	O
%	O
increase	O
and	O
ERβ	O
120	O
%	O
increase	O
gene	O
expression	O
and	O
the	O
protein	O
regulation	O
of	O
a	O
large	O
number	O
of	O
non-estrogen-responsive	O
genes	O
caused	O
by	O
17β-HSD1	O
overexpression	O
further	O
suggest	O
that	O
the	O
ligand-independent	O
transcriptions	O
of	O
ER	O
target	O
genes	O
are	O
also	O
modulated	O
by	O
the	O
enzyme	O
.	O
Because	O
in	O
vitro	O
studies	O
have	O
shown	O
that	O
both	O
ER-	O
andor	O
PR-negative	O
and	O
-positive	O
breast	O
cells	O
respond	O
in	O
a	O
stimulatory	O
and	O
inhibitory	O
fashion	O
,	O
respectively	O
,	O
to	O
5αP	O
and	O
3αHP	O
,	O
and	O
have	O
5αPR	O
and	O
3αHPR	O
,	O
the	O
present	O
results	O
also	O
may	O
have	O
implications	O
for	O
the	O
substantial	O
numbers	O
20	O
%	O
to	O
40	O
%	O
of	O
ERPR-positive	O
patients	O
who	O
fail	O
to	O
respond	O
to	O
suppression	O
of	O
estrogen	O
andor	O
progesterone	O
levels	O
or	O
actions	O
4	O
,41	O
,42	O
,	O
as	O
well	O
as	O
for	O
those	O
receptor-positive	O
tumors	O
that	O
do	O
respond	O
to	O
hormonal	O
therapies.The	O
estrogen	O
,	O
progesterone	O
,	O
and	O
HER2	O
receptor	O
status	O
of	O
the	O
samples	O
were	O
classified	O
by	O
TCC	O
pathologists	O
using	O
College	O
of	O
American	O
Pathologists	O
CAP	O
criteria	O
and	O
obtained	O
from	O
the	O
TCC	O
database	O
.	O
Various	O
genetically	O
manipulated	O
mouse	O
colonies	O
all	O
on	O
C57BL6	O
genetic	O
background	O
and	O
their	O
crossbreeding	O
schemes	O
have	O
been	O
described	O
in	O
our	O
previous	O
publication	O
14.Tumor	O
size	O
was	O
measured	O
in	O
a	O
uniform	O
manner	O
by	O
participating	O
study	O
pathologists	O
.	O
The	O
binding	O
of	O
ligand	O
induces	O
a	O
conformational	O
change	O
in	O
the	O
receptor	O
,	O
which	O
translocates	O
to	O
the	O
nucleus	O
,	O
binds	O
as	O
a	O
homodimer	O
to	O
specific	O
DNA	O
sequences	O
termed	O
estrogen	O
response	O
elements	O
ERE	O
and	O
regulates	O
the	O
transcription	O
of	O
multiple	O
target	O
genes.Because	O
in	O
vitro	O
studies	O
have	O
shown	O
that	O
both	O
ER-	O
andor	O
PR-negative	O
and	O
-positive	O
breast	O
cells	O
respond	O
in	O
a	O
stimulatory	O
and	O
inhibitory	O
fashion	O
,	O
respectively	O
,	O
to	O
5αP	O
and	O
3αHP	O
,	O
and	O
have	O
5αPR	O
and	O
3αHPR	O
,	O
the	O
present	O
results	O
also	O
may	O
have	O
implications	O
for	O
the	O
substantial	O
numbers	O
20	O
%	O
to	O
40	O
%	O
of	O
ERPR-positive	O
patients	O
who	O
fail	O
to	O
respond	O
to	O
suppression	O
of	O
estrogen	O
andor	O
progesterone	O
levels	O
or	O
actions	O
4	O
,41	O
,42	O
,	O
as	O
well	O
as	O
for	O
those	O
receptor-positive	O
tumors	O
that	O
do	O
respond	O
to	O
hormonal	O
therapies	O
.	O
Underlying	O
data	O
used	O
in	O
the	O
generation	O
of	O
this	O
figure	O
can	O
be	O
found	O
in	O
S1	O
Data.CD	O
,	O
cluster	O
of	O
differentiation	O
;	O
CreERT	O
,	O
ubiquitous	O
promoter-driven	O
Cre-recombinase	O
and	O
estrogen-receptor	O
fusion	O
protein	O
;	O
FC	O
,	O
FoxN1fxfxCreERT	O
;	O
FF	O
,	O
FoxN1fxfx	O
without	O
CreERT	O
for	O
controls	O
;	O
Foxn1	O
,	O
Forkhead	O
box	O
protein	O
N1	O
;	O
FoxN1fxfx	O
,	O
loxp-flanked	O
FoxN1	O
gene	O
;	O
mOVA-Tg	O
,	O
membrane-bound	O
ovalbumin	O
transgenic	O
mouse	O
;	O
TM	O
,	O
tamoxifen	O
;	O
WT	O
,	O
wild-type	O
.	O
There	O
was	O
no	O
significant	O
effect	O
of	O
CYP2B6	O
genotype	O
seen	O
in	O
patients	O
on	O
the	O
standard	O
arm	O
CAF	O
alone	O
,	O
in	O
the	O
absence	O
of	O
thiotepa	O
,	O
which	O
would	O
have	O
been	O
expected	O
if	O
the	O
thiotepa	O
was	O
ameliorating	O
a	O
true	O
effect	O
of	O
genotype.A	O
A	O
schematic	O
workflow	O
shows	O
that	O
young	O
FF-mOVA-Tg	O
normal	O
thymus	O
or	O
FC-mOVA-Tg	O
atrophied	O
thymus	O
mice	O
were	O
i.t	O
.	O
It	O
has	O
been	O
postulated	O
that	O
the	O
Gly538–Asp531	O
hydrogen	O
bond	O
was	O
enabled	O
by	O
the	O
flexibility	O
of	O
glycine	O
residue	O
owing	O
to	O
its	O
small	O
size	O
,	O
which	O
allows	O
it	O
to	O
adopt	O
backbone	O
conformations	O
that	O
are	O
not	O
accessible	O
for	O
other	O
amino	O
acids.Accordingly	O
,	O
HER44ICD	O
forms	O
a	O
complex	O
with	O
ER	O
and	O
is	O
translocated	O
into	O
the	O
nucleus	O
upon	O
estrogen	O
stimulus	O
,	O
and	O
the	O
nuclear	O
ER4ICD	O
complex	O
co-activates	O
ER	O
transcription	O
by	O
being	O
selectively	O
recruited	O
to	O
estrogen	O
responsive	O
gene	O
promoters	O
such	O
as	O
progesterone	O
receptor	O
PgR	O
14	O
,21	O
.	O
On	O
the	O
basis	O
of	O
the	O
main	O
role	O
exerted	O
by	O
ERα	O
in	O
the	O
development	O
and	O
progression	O
of	O
breast	O
cancer	O
and	O
considering	O
that	O
this	O
receptor	O
is	O
expressed	O
in	O
approximately	O
70	O
%	O
of	O
breast	O
tumors	O
,	O
the	O
ER	O
antagonist	O
tamoxifen	O
has	O
been	O
widely	O
used	O
,	O
although	O
its	O
effectiveness	O
is	O
limited	O
by	O
de	O
novo	O
and	O
acquired	O
resistance	O
45.Correlation	O
between	O
averaged	O
estrogen	O
I	O
and	O
progesterone	O
J	O
receptor	O
levels	O
in	O
cores	O
ERSPR	O
positive	O
=	O
1	O
and	O
ERSPR	O
negative	O
=	O
0	O
correlated	O
with	O
PrP	O
scores	O
.	O
The	O
estrogen	O
,	O
progesterone	O
,	O
and	O
HER2	O
receptor	O
status	O
of	O
the	O
samples	O
were	O
classified	O
by	O
TCC	O
pathologists	O
using	O
College	O
of	O
American	O
Pathologists	O
CAP	O
criteria	O
and	O
obtained	O
from	O
the	O
TCC	O
database.Only	O
a	O
limited	O
number	O
of	O
cases	O
had	O
detailed	O
information	O
on	O
tumor	O
characteristics	O
e.g	O
.	O
The	O
data	O
monitor	O
3	O
,389	O
genes	O
across	O
30	O
estrogen-receptor-negative	O
and	O
28	O
estrogen-receptor-positive	O
breast	O
cancer	O
samplesMost	O
of	O
the	O
human	O
breast	O
cancer	O
samples	O
we	O
studied	O
had	O
at	O
least	O
some	O
expression	O
of	O
ER	O
andor	O
PR	O
,	O
consistent	O
with	O
the	O
pattern	O
of	O
breast	O
cancers	O
seen	O
in	O
clinical	O
practice	O
.	O
This	O
results	O
in	O
a	O
conformation	O
of	O
the	O
mutant	O
receptor	O
that	O
is	O
similar	O
to	O
the	O
estrogen-bound	O
wild-type	O
receptor	O
and	O
explains	O
its	O
constitutive	O
activity.Despite	O
these	O
improvements	O
,	O
however	O
,	O
tumours	O
often	O
relapse	O
due	O
to	O
innate	O
or	O
acquired	O
resistance	O
to	O
the	O
therapeutic	O
insult	O
.	O
Other	O
studies	O
have	O
shown	O
association	O
between	O
TrxTrxR	O
and	O
the	O
estrogen	O
response	O
in	O
human	O
breast	O
cancer	O
cells.CD	O
,	O
cluster	O
of	O
differentiation	O
;	O
cKO	O
,	O
conditional	O
knockout	O
;	O
CreERT	O
,	O
ubiquitous	O
promoter-driven	O
Cre-recombinase	O
and	O
estrogen-receptor	O
fusion	O
protein	O
;	O
DP	O
,	O
double	O
positive	O
;	O
FC	O
,	O
FoxN1fxfxCreERT	O
;	O
FF	O
,	O
FoxN1fxfx	O
without	O
CreERT	O
for	O
controls	O
;	O
Foxn1	O
,	O
Forkhead	O
box	O
protein	O
N1	O
;	O
FoxN1fxfx	O
,	O
loxp-flanked	O
FoxN1	O
gene	O
;	O
mOVA-Tg	O
,	O
membrane-bound	O
ovalbumin	O
transgenic	O
mouse	O
;	O
OT-II	O
,	O
MHC	O
class-II	O
restricted	O
ovalbumin-specific	O
TCR	O
transgenic	O
mouse	O
;	O
RQ-MFI	O
,	O
relative	O
quantitative	O
Mean	O
Fluorescence	O
Intensity	O
;	O
WT	O
,	O
wild-type	O
.	O
CD	O
,	O
cluster	O
of	O
differentiation	O
;	O
CreERT	O
,	O
ubiquitous	O
promoter-driven	O
Cre-recombinase	O
and	O
estrogen-receptor	O
fusion	O
protein	O
;	O
FC	O
,	O
FoxN1fxfxCreERT	O
;	O
FF	O
,	O
FoxN1fxfx	O
without	O
CreERT	O
for	O
controls	O
;	O
Foxn1	O
,	O
Forkhead	O
box	O
protein	O
N1	O
;	O
FoxN1fxfx	O
or	O
FoxN1-floxed	O
,	O
loxp-flanked	O
FoxN1	O
gene	O
;	O
i.p	O
.	O
However	O
,	O
a	O
large	O
percentage	O
of	O
breast	O
tumors	O
are	O
ER	O
andor	O
PR	O
negative	O
4	O
,6-8	O
and	O
therefore	O
are	O
not	O
explained	O
by	O
the	O
actions	O
of	O
estrogen	O
andor	O
progesterone.Cx47	O
was	O
shown	O
to	O
interact	O
with	O
the	O
tight	O
junction	O
adaptor	O
protein	O
zonula	O
occludens	O
1	O
ZO-1	O
,	O
the	O
Y-box	O
transcription	O
factor	O
zonula	O
occludens	O
1	O
associated	O
nucleic	O
acid	O
binding	O
protein	O
ZONAB	O
which	O
regulates	O
expression	O
of	O
the	O
proliferating	O
cell	O
nuclear	O
antigen	O
PCNA	O
,	O
cyclin	O
D1	O
and	O
ErbB-2	O
.	O
Adjuvant	O
treatments	O
are	O
only	O
indicated	O
if	O
they	O
significantly	O
reduce	O
the	O
risk	O
for	O
recurrence.A	O
recent	O
single-institution	O
study	O
showed	O
that	O
50	O
%	O
of	O
high-risk	O
patients	O
with	O
TNBC	O
had	O
mutations	O
in	O
BRCA12	O
,	O
but	O
notably	O
,	O
76	O
%	O
of	O
this	O
cohort	O
had	O
a	O
family	O
history	O
of	O
breast	O
cancer	O
10	O
.	O
The	O
most	O
profound	O
effects	O
on	O
gene	O
expression	O
profiles	O
in	O
breast	O
cancer	O
are	O
related	O
to	O
estrogen	O
ER	O
,	O
and	O
proliferation	O
status	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
to	O
Human	O
Epidermal	O
Growth	O
Factor	O
Receptor	O
2	O
HER2	O
status.The	O
mechanisms	O
by	O
which	O
steroid	O
hormones	O
stimulate	O
mammary	O
epithelium	O
growth	O
are	O
controversial	O
and	O
continue	O
to	O
be	O
the	O
source	O
of	O
intense	O
investigation	O
.	O
The	O
concept	O
of	O
pre-receptor	O
regulation	O
of	O
E2	O
action	O
by	O
17β-HSD1	O
corroborates	O
with	O
its	O
effect	O
on	O
the	O
modulation	O
of	O
E2	O
responsiveness	O
of	O
pS2	O
genes	O
in	O
T47D	O
cells	O
11	O
,	O
since	O
E2	O
exerts	O
its	O
biological	O
effect	O
on	O
breast	O
cancer	O
predominantly	O
via	O
the	O
mediation	O
of	O
ERα	O
and	O
ERβ	O
23	O
,24.These	O
data	O
therefore	O
suggest	O
that	O
the	O
ERα	O
receptor	O
is	O
involved	O
in	O
the	O
augmented	O
proliferation	O
of	O
MCF-7	O
cells	O
with	O
impaired	O
SNO	O
homeostasis	O
.	O
Included	O
among	O
these	O
are	O
Sirt1	O
,	O
Hey2	O
,	O
Ncoa4	O
,	O
and	O
Foxa1	O
,	O
all	O
of	O
which	O
have	O
been	O
implicated	O
in	O
the	O
progression	O
of	O
luminal	O
breast	O
cancer	O
and	O
ER-α-dependent	O
signaling	O
,	O
as	O
well	O
as	O
ER-α	O
that	O
is	O
,	O
Esr	O
1	O
Additional	O
file	O
2.Indeed	O
,	O
a	O
whole	O
series	O
of	O
intracellular	O
events	O
,	O
such	O
as	O
the	O
rapid	O
phosphorylation	O
of	O
mitogen-activated	O
protein	O
kinases	O
MAPK	O
ERK12	O
,	O
the	O
activation	O
of	O
PI3-kinase	O
PI3K	O
and	O
phospholipase	O
C	O
PLC	O
,	O
the	O
increase	O
in	O
cAMP	O
concentrations	O
and	O
the	O
intracellular	O
calcium	O
mobilization	O
,	O
was	O
shown	O
to	O
follow	O
GPER	O
activation	O
by	O
both	O
estrogens	O
and	O
anti-estrogens	O
20	O
.	O
The	O
ER	O
can	O
regulate	O
gene	O
transcription	O
either	O
directly	O
or	O
indirectly	O
and	O
,	O
depending	O
on	O
the	O
patterns	O
of	O
co-regulator	O
recruitment	O
to	O
the	O
ligand–receptor–gene	O
assembly	O
,	O
can	O
elicit	O
either	O
the	O
stimulation	O
or	O
inhibition	O
of	O
specific	O
biological	O
effects	O
43.On	O
the	O
contrary	O
,	O
the	O
impairment	O
of	O
SNO	O
homeostasis	O
increased	O
the	O
presence	O
of	O
this	O
receptor	O
in	O
the	O
nuclear	O
fraction	O
from	O
these	O
cells	O
Figure	O
6	O
.	O
Recognition	O
that	O
breast	O
cancer	O
is	O
a	O
heterogeneous	O
disease	O
has	O
helped	O
shape	O
advances	O
in	O
therapy	O
,	O
leading	O
to	O
more	O
targeted	O
therapeutic	O
strategies	O
and	O
improved	O
survival	O
rates	O
in	O
discrete	O
disease	O
subgroups	O
1.An	O
additional	O
indicator	O
of	O
estrogen	O
signaling	O
activity	O
in	O
breast	O
tumors	O
is	O
the	O
higher	O
expression	O
of	O
known	O
estrogen-inducible	O
targets	O
,	O
such	O
as	O
progesterone	O
receptor	O
PR	O
.	O
Cox	O
proportional	O
hazard	O
models	O
were	O
constructed	O
to	O
assess	O
potential	O
confounding	O
effects	O
of	O
other	O
breast	O
cancer	O
prognostic	O
factors	O
,	O
including	O
age	O
,	O
stage	O
with	O
nodal	O
status	O
,	O
and	O
estrogen	O
and	O
progesterone	O
receptor	O
status.In	O
this	O
regard	O
,	O
the	O
opposing	O
actions	O
of	O
the	O
progesterone	O
metabolites	O
also	O
appear	O
to	O
exert	O
some	O
control	O
over	O
the	O
estrogen-regulated	O
effects	O
on	O
breast	O
cancer	O
by	O
their	O
ability	O
to	O
modulate	O
ER	O
numbers	O
in	O
ER-positive	O
cells	O
43	O
.	O
This	O
is	O
exemplified	O
by	O
the	O
advent	O
of	O
therapeutic	O
agents	O
targeting	O
estrogen-receptor	O
positive	O
ER+	O
and	O
HER2-positive	O
HER2+	O
breast	O
cancers	O
,	O
which	O
make	O
up	O
approximately	O
70	O
%	O
of	O
all	O
breast	O
tumours	O
2	O
,3.GraphPad	O
Prism	O
software	O
GraphPad	O
Software	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
was	O
used	O
to	O
compare	O
the	O
mean	O
chemokine	O
gene	O
expression	O
scores	O
with	O
a	O
Tukey	O
test	O
to	O
obtain	O
95	O
%	O
confidence	O
intervals	O
between	O
the	O
molecular	O
subtypes	O
and	O
receptor	O
statuses	O
by	O
immunohistochemistry	O
.	O
Dominant	O
distant	O
recurrence	O
site	O
was	O
1	O
soft	O
tissue	O
if	O
distant	O
lymph	O
nodes	O
or	O
skin	O
metastases	O
but	O
not	O
bone	O
or	O
visceral	O
,	O
2	O
bone	O
if	O
bone	O
metastases	O
with	O
or	O
without	O
soft	O
tissue	O
or	O
visceral	O
,	O
and	O
3	O
visceral	O
if	O
metastases	O
to	O
organs	O
with	O
or	O
without	O
bone	O
or	O
soft	O
tissue	O
involvement.More	O
recent	O
improvement	O
of	O
the	O
risk	O
assessment	O
is	O
obtained	O
through	O
the	O
molecular	O
characterization	O
of	O
the	O
tumor	O
and	O
identifies	O
patients	O
who	O
are	O
predicted	O
to	O
obtain	O
the	O
most	O
therapeutic	O
benefit	O
7-15	O
.	O
The	O
largest	O
uniform	O
group	O
retained	O
in	O
this	O
analysis	O
is	O
a	O
set	O
of	O
12	O
TFs	O
expressed	O
exclusively	O
in	O
the	O
central	O
brain	O
and	O
the	O
ventral	O
nerve	O
cord	O
for	O
example	O
,	O
Sox102F	O
and	O
a	O
few	O
previously	O
uncharacterized	O
factors	O
,	O
and	O
the	O
second	O
largest	O
comprises	O
5	O
TFs	O
in	O
the	O
trunk	O
musculature	O
and	O
related	O
mesodermal	O
structures	O
for	O
example	O
,	O
Lame	O
duck.aP-value	O
generated	O
by	O
univariate	O
Cox	O
analysis	O
.	O
20	O
and	O
identified	O
50	O
genes	O
from	O
cluster	O
B	O
that	O
were	O
significantly	O
correlated	O
with	O
PGR	O
p	O
<	O
0.05	O
in	O
both	O
the	O
van	O
de	O
Vijver	O
and	O
Wang	O
datasets	O
Figure	O
3	O
,	O
where	O
about	O
half	O
the	O
number	O
of	O
genes	O
would	O
have	O
been	O
expected	O
by	O
chance	O
p	O
<	O
0.0001	O
,	O
Fisher	O
's	O
exact.Breast	O
cancer	O
overall	O
shows	O
a	O
bimodal	O
distribution	O
with	O
respect	O
to	O
age	O
,	O
with	O
the	O
first	O
peak	O
occurring	O
at	O
age	O
50	O
years	O
more	O
commonly	O
medullary	O
or	O
inflammatory	O
breast	O
cancer	O
,	O
and	O
the	O
second	O
peak	O
reached	O
at	O
over	O
70	O
years	O
of	O
age	O
more	O
commonly	O
estrogen	O
and	O
progesterone	O
receptor-positive	O
lobular	O
or	O
mucinous	O
cancers	O
20	O
.	O
Other	O
tissues	O
exhibit	O
one	O
or	O
two	O
exclusive	O
TFs	O
for	O
example	O
:	O
midgut	O
,	O
Estrogen-receptor	O
related	O
and	O
Adult	O
enhancer	O
factor-1	O
;	O
head	O
epidermis	O
,	O
PvuII-PstI	O
homology	O
13	O
;	O
yolk	O
,	O
Cryptocephal.Doxorubicin	O
treatment	O
did	O
not	O
alter	O
the	O
hormone	O
receptor	O
status	O
of	O
ex	O
vivo	O
breast	O
tumors	O
,	O
including	O
estrogen	O
and	O
progesterone	O
receptors	O
Figure	O
S1A	O
and	O
B	O
in	O
Additional	O
file	O
1	O
.	O
Different	O
molecular	O
subtypes	O
of	O
breast	O
cancer	O
have	O
been	O
described	O
1.In	O
other	O
PQQ-producing	O
bacteria	O
,	O
the	O
peptidase-like	O
protein	O
PqqF	O
is	O
required	O
for	O
PQQ	O
synthesis	O
and	O
has	O
a	O
similar	O
function	O
as	O
the	O
TldD	O
in	O
G.	O
oxydans	O
32	O
.	O
Data	O
on	O
estrogen	O
and	O
progesterone	O
receptor	O
status	O
and	O
ERBB2	O
expression	O
were	O
obtained	O
from	O
the	O
KPNC	O
Cancer	O
Registry	O
37.Several	O
studies	O
demonstrated	O
that	O
acquired	O
resistance	O
to	O
drugs	O
that	O
block	O
ER	O
signalling	O
is	O
the	O
consequence	O
of	O
activation	O
of	O
alternative	O
survival	O
signalling	O
via	O
growth	O
factor	O
receptors	O
,	O
such	O
as	O
epidermal	O
growth	O
factor	O
receptor	O
EGFR	O
and	O
human	O
epidermal	O
growth	O
factor	O
2	O
HER2	O
,	O
that	O
enable	O
ERα	O
+	O
ve	O
breast	O
cancer	O
cells	O
to	O
escape	O
anti-estrogen	O
actions	O
and	O
contribute	O
to	O
an	O
invasive	O
phenotype	O
5	O
,6	O
.	O
Over	O
the	O
past	O
decade	O
,	O
it	O
has	O
become	O
evident	O
that	O
BC	O
represents	O
a	O
heterogeneous	O
disease	O
,	O
for	O
which	O
different	O
subtypes	O
can	O
be	O
distinguished	O
based	O
on	O
the	O
combination	O
of	O
tumor	O
grade	O
and	O
the	O
presence	O
of	O
hormone	O
receptors	O
,	O
i.e	O
.	O
,	O
estrogen	O
and	O
progesterone	O
receptor	O
status	O
;	O
therefore	O
,	O
subtype	O
analyses	O
were	O
not	O
performed	O
at	O
this	O
stage.Finally	O
,	O
to	O
assess	O
the	O
combined	O
discriminatory	O
ability	O
of	O
texture	O
analysis	O
in	O
CC	O
and	O
MLO	O
views	O
,	O
Tan	O
et	O
al	O
.	O
Overall	O
,	O
this	O
means	O
that	O
for	O
receptor-negative	O
breast	O
cancers	O
,	O
current	O
explanations	O
based	O
on	O
estrogen	O
and	O
progesterone	O
actions	O
and	O
receptors	O
are	O
inadequate	O
,	O
and	O
the	O
related	O
hormone-based	O
therapies	O
are	O
ineffective.Furthermore	O
,	O
the	O
Ki-67	O
index	O
of	O
10	O
false-negative	O
patiets	O
was	O
under	O
14	O
%	O
.	O
Underlying	O
data	O
used	O
in	O
the	O
generation	O
of	O
this	O
figure	O
panels	O
B	O
and	O
C	O
can	O
be	O
found	O
in	O
S1	O
Data.In	O
the	O
17	O
false-negative	O
patients	O
,	O
15	O
had	O
>	O
50	O
%	O
estrogen-receptor-positive	O
cells	O
,	O
and	O
13	O
also	O
had	O
>	O
20	O
%	O
progesterone-receptor-positive	O
cells	O
in	O
primary	O
tumors	O
.	O
In	O
addition	O
to	O
the	O
formation	O
of	O
ectopic	O
OFT	O
sympathetic-like	O
neurons	O
,	O
Twist1	O
;	O
Wnt1-Cre	O
CKOs	O
also	O
display	O
completely	O
penetrant	O
persistent	O
truncus	O
arteriosus	O
PTA	O
;	O
Figure	O
S5G	O
,	O
S5K	O
;	O
Table	O
S1.Tamoxifen	O
,	O
a	O
selective	O
estrogen-receptor	O
modulator	O
,	O
is	O
an	O
important	O
therapeutic	O
agent	O
for	O
patients	O
with	O
ER-positive	O
breast	O
cancers	O
26	O
.	O
Thus	O
,	O
it	O
is	O
possible	O
that	O
RXR	O
effects	O
are	O
mediated	O
through	O
interactions	O
with	O
RAR.To	O
directly	O
address	O
the	O
role	O
of	O
fork-associated	O
chromatin	O
proteins	O
in	O
histone	O
spreading	O
at	O
replication	O
,	O
we	O
examined	O
mutations	O
of	O
PCNA	O
and	O
Chromatin	O
Assembly	O
Factor	O
CAF-1	O
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
replication-coupled	O
histone	O
deposition	O
48	O
,49	O
.	O
Since	O
p53	O
also	O
appeared	O
to	O
be	O
involved	O
in	O
the	O
observed	O
increase	O
in	O
proliferation	O
,	O
the	O
subcellular	O
distribution	O
of	O
this	O
protein	O
was	O
also	O
analyzed.In	O
contrast	O
,	O
most	O
observational	O
studies	O
either	O
report	O
no	O
influence	O
of	O
or	O
a	O
favorable	O
effect	O
of	O
MHT	O
on	O
prognostic	O
variables	O
such	O
as	O
tumor	O
size	O
,	O
lymph	O
node	O
involvement	O
,	O
tumor	O
grade	O
,	O
or	O
receptor	O
status	O
3-14	O
.	O
,	O
prior	O
hormonal	O
therapy	O
status	O
,	O
prior	O
neoadjuvant	O
chemotherapy	O
status	O
,	O
de	O
novo	O
disease	O
status	O
,	O
race	O
,	O
estrogenprogesterone	O
receptor	O
status	O
,	O
and	O
selected	O
biomarkers	O
.	O
Estrogen	O
and	O
progesterone	O
receptors	O
were	O
positive	O
if	O
>	O
1	O
%	O
immunohistochemical	O
IHC	O
staining	O
was	O
noted	O
,	O
and	O
HER2	O
status	O
was	O
positive	O
if	O
3+	O
by	O
IHC	O
or	O
with	O
a	O
positive	O
ratio	O
by	O
in	O
situ	O
hybridization	O
assay.A	O
total	O
of	O
6	O
,272	O
BRCA2	O
carriers	O
from	O
39	O
studies	O
Table	O
2	O
and	O
14	O
countries	O
contributed	O
DNA	O
samples	O
for	O
this	O
project	O
.	O
The	O
detailed	O
multilevel	O
alterations	O
induced	O
by	O
JARID1b	O
were	O
analyzed	O
in	O
a	O
pathway-specific	O
manner	O
to	O
develop	O
a	O
diagnostic	O
test.It	O
is	O
well	O
known	O
that	O
risk	O
of	O
breast	O
cancer	O
is	O
linked	O
with	O
endogenous	O
estrogen	O
and	O
progesterone	O
exposure	O
,	O
including	O
early	O
menarche	O
,	O
late	O
menopause	O
,	O
nulliparity	O
,	O
age	O
at	O
first	O
birth	O
21–25	O
,	O
as	O
well	O
as	O
exogenous	O
exposure	O
to	O
hormone	O
replacement	O
26	O
.	O
PR	O
Progesterone	O
receptorEstrogen	O
and	O
progesterone	O
receptors	O
were	O
positive	O
if	O
>	O
1	O
%	O
immunohistochemical	O
IHC	O
staining	O
was	O
noted	O
,	O
and	O
HER2	O
status	O
was	O
positive	O
if	O
3+	O
by	O
IHC	O
or	O
with	O
a	O
positive	O
ratio	O
by	O
in	O
situ	O
hybridization	O
assay	O
.	O
The	O
early	O
discovery	O
8	O
of	O
a	O
transmembrane	O
receptor	O
able	O
to	O
mediate	O
estrogen	O
responsiveness	O
in	O
ER-negative	O
breast	O
cancer	O
cells	O
was	O
then	O
confirmed	O
by	O
several	O
reports	O
by	O
which	O
GPER	O
was	O
considered	O
as	O
a	O
genuine	O
ER	O
10	O
,19.We	O
found	O
that	O
the	O
two	O
ER+	O
samples	O
that	O
successfully	O
grew	O
propagatable	O
tumors	O
in	O
SCID	O
mice	O
lost	O
their	O
ER	O
expression	O
generally	O
by	O
the	O
second	O
passage	O
even	O
when	O
the	O
mice	O
were	O
supplemented	O
with	O
estrogen	O
.	O
Together	O
,	O
these	O
results	O
indicate	O
that	O
high	O
PrP	O
mRNA	O
levels	O
are	O
associated	O
with	O
poorer	O
prognosis	O
breast	O
cancers.Briefly	O
,	O
FoxN1fxfx	O
18	O
mice	O
were	O
crossbred	O
with	O
CMV-promoter-driven	O
CreERT	O
ubiquitous	O
promoter-driven	O
Cre-recombinase	O
and	O
estrogen-receptor	O
fusion	O
protein	O
Tg	O
mice	O
,	O
then	O
with	O
rag-gfp	O
reporter	O
mice	O
.	O
One	O
group	O
was	O
characterized	O
by	O
over-expression	O
of	O
ERBB2	O
,	O
the	O
steroid	O
hormone	O
receptor	O
AR	O
,	O
and	O
genes	O
related	O
to	O
steroid	O
estrogen	O
response	O
such	O
as	O
GATA3	O
,	O
TFF1	O
,	O
and	O
DNALI1	O
.	O
In	O
other	O
PQQ-producing	O
bacteria	O
,	O
the	O
peptidase-like	O
protein	O
PqqF	O
is	O
required	O
for	O
PQQ	O
synthesis	O
and	O
has	O
a	O
similar	O
function	O
as	O
the	O
TldD	O
in	O
G.	O
oxydans	O
32.The	O
domain	O
architecture	O
of	O
the	O
ER	O
includes	O
an	O
N-terminal	O
hormone-independent	O
transactivation	O
domain	O
AF1	O
,	O
a	O
highly	O
conserved	O
DNA-binding	O
domain	O
that	O
mediates	O
specific	O
recognition	O
of	O
ERE	O
,	O
a	O
hinge	O
domain	O
that	O
separates	O
the	O
DNA-binding	O
domain	O
from	O
the	O
ligand-binding	O
domain	O
LBD	O
,	O
a	O
LBD	O
that	O
contains	O
the	O
hormone	O
binding	O
pocket	O
,	O
and	O
a	O
second	O
transactivation	O
domain	O
AF2	O
in	O
the	O
C-terminus	O
that	O
is	O
activated	O
in	O
response	O
to	O
ligand	O
binding	O
7	O
.	O
HER44ICD	O
possesses	O
constitutively	O
active	O
kinase	O
activity	O
and	O
is	O
a	O
chaperone	O
for	O
nuclear	O
entry	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
5A	O
STAT5A.Since	O
their	O
discovery	O
,	O
microRNAs	O
have	O
been	O
implicated	O
in	O
many	O
steps	O
of	O
cancer	O
development	O
and	O
progression	O
.	O
The	O
results	O
in	O
this	O
study	O
are	O
consistent	O
with	O
that	O
in	O
other	O
cohorts	O
of	O
triple-negative	O
breast	O
cancer	O
patients	O
,	O
in	O
whom	O
11	O
%	O
to	O
39	O
%	O
have	O
germline	O
mutations	O
in	O
BRCA1	O
and	O
BRCA2	O
3	O
,6	O
,20-23	O
,	O
and	O
cohorts	O
of	O
estrogen-receptor-negative	O
breast	O
cancer	O
patients	O
,	O
of	O
whom	O
24	O
%	O
to	O
29	O
%	O
have	O
germline	O
mutations	O
in	O
BRCA1	O
and	O
BRCA2	O
4	O
,6	O
,24	O
,25.Cox	O
proportional	O
hazard	O
models	O
were	O
constructed	O
to	O
assess	O
potential	O
confounding	O
effects	O
of	O
other	O
breast	O
cancer	O
prognostic	O
factors	O
,	O
including	O
age	O
,	O
stage	O
with	O
nodal	O
status	O
,	O
and	O
estrogen	O
and	O
progesterone	O
receptor	O
status	O
.	O
21.The	O
Croce	O
group	O
has	O
shown	O
that	O
miRNAs	O
are	O
aberrantly	O
expressed	O
in	O
human	O
breast	O
cancers	O
and	O
that	O
this	O
expression	O
correlated	O
to	O
multiple	O
features	O
of	O
cancer	O
,	O
including	O
estrogen	O
and	O
progesterone	O
receptor	O
status	O
,	O
stage	O
,	O
and	O
indices	O
of	O
proliferation	O
and	O
invasion	O
7	O
.	O
However	O
,	O
little	O
has	O
been	O
explored	O
regarding	O
the	O
hormone-independent	O
effect	O
of	O
tamoxifen	O
in	O
breast	O
cancer	O
cells.The	O
following	O
clinical	O
data	O
were	O
included	O
:	O
age	O
,	O
menopausal	O
status	O
,	O
tumor	O
stage	O
on	O
basis	O
of	O
pTNM	O
classification	O
,	O
estrogenprogesterone	O
receptor	O
ERPR	O
status	O
,	O
Her2Neu	O
receptor	O
status	O
,	O
differential	O
grade	O
of	O
the	O
tumor	O
based	O
on	O
the	O
Bloom-Richardson	O
method	O
,	O
adjuvant	O
treatment	O
,	O
date	O
of	O
recurrence	O
if	O
occurred	O
,	O
location	O
of	O
recurrence	O
local	O
versus	O
distant	O
,	O
date	O
of	O
breast	O
cancer-associated	O
death	O
or	O
non-breast	O
cancer-associated	O
death	O
.	O
Similar	O
high	O
constitutive	O
activation	O
of	O
ESR1	O
mutants	O
except	O
S463P	O
with	O
concomitant	O
increase	O
in	O
the	O
transcript	O
levels	O
of	O
estrogen-responsive	O
genes	O
such	O
as	O
GREB1	O
,	O
MYC	O
,	O
PGR	O
and	O
TFF1	O
and	O
reduced	O
,	O
but	O
retained	O
,	O
response	O
to	O
anti-estrogens	O
was	O
noted	O
by	O
Toy	O
and	O
coworkers	O
28.In	O
estrogen-starved	O
MCF-7	O
cells	O
,	O
confocal	O
analysis	O
revealed	O
a	O
prevalent	O
nuclear	O
distribution	O
of	O
p53	O
protein	O
,	O
which	O
was	O
not	O
modified	O
by	O
any	O
of	O
the	O
treatments	O
.	O
Only	O
a	O
limited	O
number	O
of	O
cases	O
had	O
detailed	O
information	O
on	O
tumor	O
characteristics	O
e.g	O
.	O
Furthermore	O
,	O
preliminary	O
comparisons	O
of	O
the	O
parenchymal	O
patterns	O
of	O
estrogen-receptor	O
positive	O
ER+	O
and	O
negative	O
ER–	O
cancer	O
cases	O
measured	O
with	O
the	O
same	O
methodology	O
51	O
showed	O
that	O
subtype-specific	O
breast	O
cancer	O
risk	O
assessment	O
based	O
on	O
mammographic	O
textures	O
may	O
also	O
be	O
feasible	O
79.Our	O
TMA	O
analyses	O
of	O
human	O
breast	O
carcinomas	O
showed	O
that	O
a	O
high	O
ER	O
stress	O
marker	O
BiP	O
levels	O
were	O
associated	O
with	O
higher	O
PrP	O
levels	O
,	O
b	O
both	O
BiP	O
and	O
PrP	O
levels	O
were	O
higher	O
in	O
grade	O
3	O
tumors	O
compared	O
to	O
grade	O
1	O
tumors	O
,	O
and	O
c	O
levels	O
of	O
PrP	O
correlate	O
with	O
estrogen	O
and	O
progesterone	O
receptor	O
negative	O
tumors	O
.	O
Lastly	O
,	O
we	O
describe	O
that	O
the	O
ER	O
stress-mediated	O
increase	O
in	O
PrP	O
levels	O
is	O
associated	O
with	O
increased	O
cellular	O
survival	O
in	O
human	O
breast	O
cancers.Additionally	O
,	O
binding	O
of	O
estrogen	O
to	O
the	O
ER	O
can	O
be	O
modulated	O
by	O
progesterone	O
44	O
.	O
The	O
data	O
in	O
Additional	O
data	O
file	O
4	O
monitor	O
3	O
,389	O
genes	O
across	O
30	O
estrogen-receptor-negative	O
and	O
28	O
estrogen-receptor-positive	O
breast	O
cancer	O
samples.Given	O
the	O
multitude	O
of	O
interacting	O
partners	O
of	O
RXRs	O
over	O
19	O
described	O
40	O
,	O
dissecting	O
the	O
mechanism	O
of	O
RXR	O
action	O
on	O
the	O
promoter	O
of	O
AQP5	O
and	O
other	O
genes	O
will	O
require	O
a	O
very	O
detailed	O
examination	O
.	O
For	O
tumor	O
grade	O
,	O
receptor	O
status	O
,	O
and	O
histological	O
type	O
,	O
the	O
only	O
significant	O
difference	O
reported	O
in	O
the	O
randomized	O
trials	O
was	O
that	O
women	O
treated	O
with	O
estrogen	O
alone	O
were	O
more	O
likely	O
to	O
have	O
lobular	O
tumors	O
than	O
ductal	O
tumors.aOnly	O
patients	O
with	O
known	O
clinical	O
information	O
were	O
considered	O
for	O
comparison	O
between	O
tamoxifen-treated	O
cohort	O
1	O
and	O
untreated	O
patients	O
.	O
This	O
cell	O
line	O
,	O
derived	O
from	O
a	O
ductal	O
breast	O
carcinoma	O
,	O
is	O
estrogen	O
negative	O
,	O
progesterone	O
receptor	O
negative	O
and	O
ERBB2	O
positive	O
,	O
and	O
has	O
been	O
particularly	O
well	O
studied	O
at	O
the	O
molecular	O
level	O
2	O
,7	O
,23.The	O
index	O
thus	O
designed	O
was	O
applied	O
to	O
a	O
breast	O
cancer	O
dataset	O
that	O
included	O
both	O
DNA	O
copy	O
number	O
and	O
mRNA	O
expression	O
data	O
,	O
showing	O
that	O
inferred	O
JARID1b	O
activity	O
was	O
prognostic	O
for	O
estrogen-receptor-positive	O
disease	O
.	O
,	O
estrogen	O
ER	O
,	O
progesterone	O
PR	O
and	O
human	O
epidermal	O
growth	O
factor	O
receptor-2	O
HER2	O
.	O
In	O
the	O
Women	O
's	O
Health	O
Initiative	O
randomized	O
clinical	O
trials	O
2	O
,30	O
,	O
women	O
treated	O
with	O
estrogen	O
alone	O
or	O
treated	O
with	O
estrogen–progestin	O
had	O
slightly	O
larger	O
tumors	O
and	O
a	O
higher	O
prevalence	O
of	O
lymph	O
node	O
involvement	O
than	O
untreated	O
women.Other	O
tissues	O
exhibit	O
one	O
or	O
two	O
exclusive	O
TFs	O
for	O
example	O
:	O
midgut	O
,	O
Estrogen-receptor	O
related	O
and	O
Adult	O
enhancer	O
factor-1	O
;	O
head	O
epidermis	O
,	O
PvuII-PstI	O
homology	O
13	O
;	O
yolk	O
,	O
Cryptocephal	O
.	O
The	O
modified	O
method	O
17-19	O
includes	O
upward	O
adjustments	O
for	O
TNBC	O
+4	O
,	O
estrogen-negative	O
+1	O
,	O
and	O
high-grade	O
invasive	O
cancers	O
+2	O
,	O
and	O
downward	O
adjustments	O
for	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
HER2-positive	O
-4	O
or	O
estrogen-receptor	O
positive	O
-1	O
,	O
lobular	O
-2	O
,	O
and	O
low-grade	O
noninvasive	O
cancers	O
-2.The	O
modified	O
method	O
17-19	O
includes	O
upward	O
adjustments	O
for	O
TNBC	O
+4	O
,	O
estrogen-negative	O
+1	O
,	O
and	O
high-grade	O
invasive	O
cancers	O
+2	O
,	O
and	O
downward	O
adjustments	O
for	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
HER2-positive	O
-4	O
or	O
estrogen-receptor	O
positive	O
-1	O
,	O
lobular	O
-2	O
,	O
and	O
low-grade	O
noninvasive	O
cancers	O
-2	O
.	O
Furthermore	O
,	O
CYP2D6*4	O
,	O
which	O
was	O
included	O
to	O
account	O
for	O
the	O
possible	O
differential	O
effect	O
of	O
variable	O
tamoxifen	O
metabolism	O
on	O
outcome	O
among	O
patients	O
whose	O
tumors	O
were	O
estrogen-receptor	O
positive	O
,	O
was	O
included	O
in	O
all	O
the	O
models	O
tested	O
,	O
and	O
there	O
was	O
no	O
independent	O
effect	O
of	O
this	O
genotype	O
,	O
nor	O
did	O
it	O
appear	O
to	O
confound	O
the	O
main	O
effects.Given	O
the	O
modification	O
of	O
ER	O
activity	O
by	O
its	O
cofactors	O
through	O
their	O
physical	O
and	O
functional	O
interactions	O
16	O
,	O
the	O
cofactor	O
proteins	O
that	O
bind	O
to	O
ER	O
may	O
be	O
as	O
important	O
as	O
the	O
receptor	O
itself	O
in	O
mediating	O
transcriptional	O
response	O
to	O
estrogen	O
exposure	O
17	O
.	O
Breast	O
cancer	O
overall	O
shows	O
a	O
bimodal	O
distribution	O
with	O
respect	O
to	O
age	O
,	O
with	O
the	O
first	O
peak	O
occurring	O
at	O
age	O
50	O
years	O
more	O
commonly	O
medullary	O
or	O
inflammatory	O
breast	O
cancer	O
,	O
and	O
the	O
second	O
peak	O
reached	O
at	O
over	O
70	O
years	O
of	O
age	O
more	O
commonly	O
estrogen	O
and	O
progesterone	O
receptor-positive	O
lobular	O
or	O
mucinous	O
cancers	O
20.The	O
impairment	O
of	O
the	O
TrxTrxR	O
system	O
has	O
thus	O
been	O
described	O
to	O
increase	O
the	O
progesterone	O
receptor	O
expression	O
in	O
MCF-7	O
cells	O
in	O
response	O
to	O
estrogen	O
30	O
.	O
H.	O
Comparison	O
of	O
the	O
mean	O
intensity	O
score	O
mean	O
±	O
SEM	O
of	O
PrP	O
immunostaining	O
in	O
breast	O
tissue	O
cores	O
showing	O
Low	O
0	O
to	O
1	O
or	O
High	O
BiP	O
2	O
to	O
3	O
immunostaining	O
scores.We	O
named	O
this	O
model	O
the	O
FC	O
FoxN1fxfxCreERT	O
mouse	O
and	O
FF	O
FoxN1fxfx	O
without	O
CreERT	O
for	O
controls	O
mouse	O
.	O
The	O
authors	O
showed	O
a	O
collective	O
discriminatory	O
capacity	O
of	O
AUC	O
=	O
0.85	O
,	O
with	O
the	O
fractal	O
dimension	O
,	O
run-length	O
,	O
co-occurrence	O
,	O
and	O
gray-level	O
histogram	O
features	O
being	O
more	O
frequently	O
selected	O
than	O
local	O
binary	O
and	O
edge-enhancing	O
index	O
features	O
in	O
classification	O
models.Therefore	O
,	O
our	O
study	O
demonstrated	O
that	O
overexpression	O
of	O
the	O
tldD	O
gene	O
could	O
increase	O
PQQ	O
level	O
by	O
12.30	O
%	O
in	O
G.	O
oxydans	O
ZJU5	O
compared	O
with	O
that	O
of	O
G.	O
oxydans	O
ZJU4	O
Table	O
2	O
.	O
Tamoxifen	O
,	O
a	O
selective	O
estrogen-receptor	O
modulator	O
,	O
is	O
an	O
important	O
therapeutic	O
agent	O
for	O
patients	O
with	O
ER-positive	O
breast	O
cancers	O
26.This	O
results	O
in	O
a	O
conformation	O
of	O
the	O
mutant	O
receptor	O
that	O
is	O
similar	O
to	O
the	O
estrogen-bound	O
wild-type	O
receptor	O
and	O
explains	O
its	O
constitutive	O
activity	O
.	O
Underlying	O
data	O
used	O
in	O
the	O
generation	O
of	O
panels	O
A	O
and	O
B	O
can	O
be	O
found	O
in	O
S1	O
Data.Of	O
note	O
,	O
genotyping	O
for	O
CYP2D6*4	O
was	O
included	O
to	O
account	O
for	O
any	O
possible	O
differential	O
effect	O
of	O
variable	O
tamoxifen	O
metabolism	O
on	O
outcome	O
among	O
patients	O
whose	O
tumors	O
were	O
estrogen-receptor	O
positive	O
.	O
Besides	O
loss	O
of	O
channel	O
function	O
,	O
loss	O
of	O
intracellular	O
protein	O
interaction	O
may	O
also	O
be	O
relevant	O
for	O
the	O
phenotype	O
of	O
Cx47M282T	O
expressing	O
mice	O
and	O
for	O
PMLD.The	O
early	O
discovery	O
8	O
of	O
a	O
transmembrane	O
receptor	O
able	O
to	O
mediate	O
estrogen	O
responsiveness	O
in	O
ER-negative	O
breast	O
cancer	O
cells	O
was	O
then	O
confirmed	O
by	O
several	O
reports	O
by	O
which	O
GPER	O
was	O
considered	O
as	O
a	O
genuine	O
ER	O
10	O
,19	O
.	O
Genomic	O
amplification	O
of	O
BAF57SMARCE1	O
,	O
a	O
core	O
subunit	O
of	O
human	O
SWISNF	O
complexes	O
that	O
plays	O
a	O
role	O
in	O
interaction	O
with	O
transcription	O
factors	O
and	O
chromatin	O
,	O
has	O
been	O
linked	O
to	O
high	O
risk	O
of	O
recurrence	O
of	O
estrogenprogesterone	O
receptor-negative	O
breast	O
tumors	O
12.We	O
defined	O
hormone	O
receptor	O
positive	O
patients	O
as	O
estrogen	O
andor	O
progesterone	O
receptor	O
positive	O
HR	O
positive	O
and	O
HR-negative	O
if	O
negative	O
for	O
both	O
.	O
They	O
have	O
shown	O
potential	O
roles	O
as	O
predictors	O
of	O
treatment	O
outcomes	O
and	O
microRNA	O
profiling	O
of	O
tumors	O
may	O
have	O
the	O
ability	O
to	O
predict	O
prognosis	O
and	O
identify	O
tumor	O
subtypes	O
5.The	O
FoxN1fxfx	O
cKO	O
was	O
through	O
either	O
a	O
TM-induced	O
acute	O
deletion	O
or	O
CreERT	O
autoleakage-mediated	O
time-course	O
deletion	O
12	O
.	O
